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Abstract
Central to the goals of public health are obtaining and interpreting timely and relevant
information for the benefit of humanity. In this dissertation, we propose methods to monitor
and assess the spread HIV in a more rapid manner, as well as to improve decisions regarding
patient treatment options.
In Chapter 1, we propose a method, extending the previously proposed dual-testing
algorithm and augmented cross-sectional design, for estimating the HIV incidence rate in
a particular community. Compared to existing methods, our proposed estimator allows for
shorter follow-up time and does not require estimation of the mean window period, a crucial,
but often unknown, parameter. The estimator performs well in a wide range of simulation
settings. We discuss when this estimator would be expected to perform well and oﬀer design
considerations for the implementation of such a study.
Chapters 2 and 3 are concerned with obtaining a more complete understanding of the
impact of treatment in randomized clinical trials in which multiple patient outcomes are
recorded. Chapter 2 provides an illustration of methods that may be used to address con-
cerns of both risk-benefit analysis and personalized medicine simultaneously, with a goal of
successfully identifying patients who will be ideal candidates for future treatment. Risk-
benefit analysis is intended to address the multivariate nature of patient outcomes, while
“personalized medicine” is concerned with patient heterogeneity, both of which complicate
the determination of a treatment’s usefulness. A third complicating factor is the duration of
treatment use. Chapter 3 features proposed methods for assessing the impact of treatment
as a function of time, as well as methods for summarizing the impact of treatment across a
iii
range of follow-up times.
Chapter 4 addresses the issue of meta-analysis, a commonly used tool for combining
information for multiple independent studies, primarily for the purpose of answering a clinical
question not suitably addressed by any one single study. This approach has proven highly
useful and attractive in recent years, but often relies on parametric assumptions that cannot
be verified. We propose a non-parametric approach to meta-analysis, valid in a wider range
of scenarios, minimizing concerns over compromised validity.
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1.1 Introduction
Cross-sectional HIV incidence estimation based on a sensitive and less-sensitive test oﬀers
great advantages over the traditional cohort study for incidence estimation (Brookmeyer
and Quinn, 1995; Janssen et al., 1998). Based on features of the evolving HIV-1 antibody
response during the months after primary HIV-1 infection, several enzyme-immunoassays
(EIAs) have been developed to diﬀerentiate early and long-standing HIV infections. Sub-
jects who test positive on an EIA sensitive assay but negative on a less-sensitive assay are
identified as early infections while subjects who are reactive on both are considered to be
long-term HIV infections. An incidence estimate can be obtained by equating incidence
with prevalence of persons with early infection divided by the time between seroconversion
on the 2 tests (commonly termed “window period”). This approach has attracted much at-
tention. One popular assay is the IgG capture BED EIA (BED) assay (Parekh et al., 2002).
Balasubramanian and Lagakos (2010) postulate a longitudinal history statistical model of
HIV seconversion and subsequent reactivity to a less sensitive assay, and show that the
cross-sectional estimator arises as a maximum likelihood estimator under this model. They
further extend this method to allow the assessment of covariate eﬀects. However, concerns
have been raised in recent years regarding the reliability of this method (Sakarovitch et al.,
2007). Some less-sensitive tests, for example, the BED assay, may yield false negative re-
sults; that is, subjects may remain negative to the less-sensitive assay long after they have
been infected (Hargrove et al., 2008). It has been noted that if such a subpopulation exists,
then the original cross-sectional incidence estimator must be adjusted to account for this
fact (Brookmeyer, 2009; Welte et al., 2009; Wang and Lagakos, 2009).
Recently, Wang and Lagakos (2010) proposed an augmented cross-sectional study design
which adds a longitudinal component to the traditional cross-sectional study by following
forward those subjects who test positive on the sensitive assay and test negative on the
less-sensitive assay until either they become reactive to the less-sensitive assay or for a
predetermined length of follow-up time τ , whichever occurs first. The augmented cross-
2
sectional study provides one way to estimate the size of the subpopulation who will remain
negative permanently on the less-sensitive test. An estimate of the false negative rate can
be obtained by calculating the proportion of subjects who remain negative at the end of the
follow-up period. An underlying assumption for an unbiased estimate of the false negative
rate is that τ is chosen to be long enough so that those who have not become reactive to
the less-sensitive assay by the end of the follow-up period will remain negative indefinitely.
Thus, the choice of τ requires knowledge of an upper limit for the window period (W∗) among
those who will become reactive. Two issues arise. First, does there exist a subpopulation
where infected subjects would remain nonreactive to the less-sensitive assay permanently?
If so, what is the upper limit of the window period among those who will become reactive?
Although there is some belief that those who will become reactive to the BED assay will do
so within a year, considerable uncertainty regarding this upper limit exists.
In this paper, we assess the impact of varying follow-up time on estimating HIV inci-
dence within the context of an augmented cross-sectional design, evaluate the robustness of
incidence estimators to the assumptions about the existence and size of the subpopulation
where infected subjects will remain negative permanently on the less-sensitive test, and pro-
pose a new estimator based on abbreviated follow-up time (AF). In Section 2.1, we generalize
the likelihood function in Wang and Lagakos (2010) by incorporating length of follow-up and
analyze the behavior of the estimators when diﬀerent underlying models are assumed. In
Section 2.2, we introduce the AF estimator, which allows shorter follow-up time than the
original estimator based on the augmented design and does not require estimation of the
window period. In Section 3, we use simulations to compare the performance of various
estimators. In Section 4, we discuss areas of future research. All proofs are relegated to
Appendices.
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1.2 Methods
1.2.1 Notation and Model
We consider the four-state progressive-disease model as in Section 3 of Wang and Lagakos
(2010). Here, State 1 represents the pre-seroconversion state (uninfected or infected but not
detectable by the sensitive test). State 2 represents the “recent infection” state, in which
an infected subject is detectable by the sensitive diagnostic test, but not yet by the less-
sensitive test (though he/she will eventually test positive). State 3 represents the “nonrecent
infection” state in which an infected individual is detectable by both the sensitive and less-
sensitive diagnostic tests. State 4 represents subjects who will remain nonreactive to the
less-sensitive assay permanently.
Using the same notation as in Wang and Lagakos (2010), let time 0 denote birth of an
individual and T denote the calendar time of HIV seroconversion. Let f(u), λ(u), and F (u)
denote the density, incidence rate, and cumulative distribution functions of T at time u ≥ 0.
Let W denote the individual’s time spent in State 2, with cumulative distribution function
G(·). Denote the upper limit of support for W by W ∗. Let µ = E(W ) denote the mean time
from infection to testing positive on less-sensitive test, amongst the population who will test
positive eventually. Let p denote the proportion of such patients among all infected subjects.
Let t denote the calendar time of the cross-sectional sample. As in Wang and Lagakos (2010),
we assume that T is independent of W and f(u) = f , for u ∈ (t −W ∗, t). Our goal is to
make inferences about λ(t) = f/{1 − F (t)}, the HIV incidence rate at the time, t, of the
cross-sectional sample. Hereafter we denote λ(t) as λ for simplicity because the remainder
of the paper focuses on a fixed calendar time t, the time at which the cross-sectional sample
is obtained.
Suppose that a random sample of size N is drawn from a population of asymptomatic
individuals at calendar time t, and tested using both a sensitive and less-sensitive diagnostic
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test. Let N1, N2, and N3 denote the numbers of subjects who test negative on both tests
(State 1), positive only on the sensitive test (State 2 or 4), and positive on both tests (State
3), respectively. In an augmented cross-sectional study, we will follow and periodically retest
the N2 subjects who test negative on the less-sensitive test for some time period τ , at
which time we will have observed n1τ transitions to the “non-recent infection” state. Let
n0τ = N2−n1τ denote the number of remaining subjects, including subjects who may become
positive on the less-sensitive test at a later time as well as those who will remain negative
permanently. Let X denote the forward recurrence time, which represents the time elapsed
from t until entrance into State 3. Let h(x | t) and H(x | t) denote the conditional density
and cumulative function of X. Each of the n1τ subjects gives rise to an interval censored
observation [ai, bi] of the forward recurrence time Xi, where ai denotes the elapsed time
between t and the last negative test result and bi denotes the elapsed time between t and
the first positive test result. Let n1 and n0 denote the true number of subjects who are in
State 2 and 4, respectively, at time t.
Let π1(t), π2(t), π3(t), and π4(t) denote the prevalence probabilities in State 1, 2, 3, and
4 at time t, respectively. The likelihood function corresponding to an arbitrary τ is given by
(see Appendix 1):
L ={π1(t)}N1{π2(t)H(τ | t)}n1τ{π3(t)}N3 [π4(t) + π2(t){1−H(τ | t)}]n0τ
×
n1τ￿
i=1
H(bi | t)−H(ai | t)
H(τ | t)
=φN1{p(1− φ− φλµ)}N3(φλpµ)n1τ [(1− p)(1− φ) + φλµp{1−H(τ | t)}]n0τ (1.1)
×
n1τ￿
i=1
{H(bi | t)−H(ai | t)}
where φ = 1− F (t) and
H(x | t) =
￿ x
0
1−G(v)
µ
dv (1.2)
as shown in Wang and Lagakos (2010). This relationship implies that H(·) is uniquely
determined once G(·) is specified. Because the right hand side of (1.2) is free of t, and the
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remainder of the paper focuses on a fixed time t, we hereafter use H(x) to represent H(x | t)
for simplicity. We note that without parametric assumptions about the distribution G(·), the
parameters (µ, p) are non-identifiable, as the true state of subjects who have yet to transition
to State 3 by the end of follow-up cannot be known. Even with a parametric assumption, the
parameters (µ, p) are weakly identifiable, in the sense that the likelihood function is relatively
flat near the true parameter values, resulting in a near-singular information matrix. Below
we attempt to address this issue by making additional assumptions on either p or G(τ).
Assume p = 1
If all infected subjects will eventually test positive on the less-sensitive test, then p = 1 and
the above likelihood reduces to
L =φN1(1− φ− φλµ)N3(φλµ)n1τ
n1τ￿
i=1
{H(bi)−H(ai)}[φλµ{1−H(τ)}]n0τ
=φN1(1− φ− φλµ)N3(φλµ)N2
N2￿
i=1
{H(bi)−H(ai)}. (1.3)
For those subjects who have not become reactive to the less-sensitive assay at time τ , we
let ai = τ and bi = ∞. The above likelihood is given in equation (5) of Wang and Lagakos
(2010). The assumption of p = 1 implies that all recently infected individuals will eventually
test positive on the less-sensitive test. If this assumption is true, then the resulting estimator
λˆA =
N2
N1µˆ
(1.4)
(hereafter referred to as Estimator A) is consistent regardless of follow-up time τ , provided
that the parametric assumption about the underlying distribution for sojourn time is correct.
Here we use µˆ to denote the maximum likelihood estimate of µ.
However, if this assumption of p = 1 is violated, then it was shown in Wang and Lagakos
(2009) that this estimator λˆA converges in probability to
pφλµ+ (1− p)(1− φ)
φµτA
(1.5)
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where µτA is the probability limit of the (biased) estimate of µ resulting from τ units of
follow-up and the (improper) assumption that p = 1.
Under mild violations of this assumption (p = .99), we find that the asymptotic bias
is modest for τ ≤ µ, but then increases quickly, with E(λˆA)/λ > 1.25 when τ ≥ 2µ under
many plausible scenarios, with the degree of bias increasing with the population prevalence,
leading to a significant overestimation of the true incidence rate.
Assume that follow-up time is longer than W ∗
When the follow-up time τ is longer thanW ∗, we have H(τ) = 1, and the likelihood function
(1.1) reduces to
L = φN1{p(1− φ− φλµ)}N3(φλpµ)n1τ{(1− p)(1− φ)}n0τ
n1τ￿
i=1
{H(bi)−H(ai)}. (1.6)
This corresponds to the scenario described in Section 3 of Wang and Lagakos (2010) when
all individuals in State 2 are followed until they have entered State 3. If we know W ∗ up to
an upper limit, then we can choose τ > W ∗, so that H(τ) = 1. The resulting estimator,
λˆB =
n1τ
N1pˆτ µˆτ
(1.7)
(hereafter referred to as Estimator B) is consistent, where pˆτ = (N3 + n1τ )/(N3 +N2).
If this assumption τ > W ∗ is violated, then some of the n1 − n1τ truly recently infected
individuals who have not transitioned during the follow-up period may be incorrectly classi-
fied as “long-term non-progressors”. It is shown in Appendix 2 that this estimator converges
in probability to
λ
µ
µτB
(1− φ)H(τ)
1− φ− φλµ{1−H(τ)} (1.8)
where µτB is the probability limit of the (biased) estimate of µ resulting from τ units of
follow-up and the (improper) assumption that H(τ) = 1.
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In Figure 1.1, we show an example of the probability limits of Estimators A and B as
a function of follow-up time τ , for p = 1 (Fig. 1.1(a)) and p = .95 (Fig. 1.1(b)). For this
example, we assumed prevalence and incidence values of 15% and 2%, respectively, with
mean window period of 6 months and the sojourn times following a Weibull distribution
with shape parameter k = 2. We used (1.5) and (1.8) to calculate the probability limits
at each time τ . Asymptotic values of µˆτA and µˆτB were estimated by simulating data
representing approximately one million subjects with biweekly follow-up. The asymptotic
bias of Estimator A is seen to be quite sensitive to departures from the assumption of p = 1,
and increases as τ increases. The limit of Estimator A rises to 2.9% for τ = 52 and 3.4%
when τ = 78 weeks. The asymptotic bias of Estimator B is comparatively small even when
τ is much smaller than W ∗.
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Figure 1.1: Probability Limits of Estimator A (open circles) and Estimator B (solid circles)
for Various τ and p, with φ = .85, λ = .02, and Assuming that G(·) is Weibull with Mean
.5 and Shape Parameter k = 2.
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Assume p = p0 < 1
If the assumption of p = 1 is likely to be violated, and we are unable to posit a value for W ∗,
we can assume a pre-specified value of p (denoted p0), possibly on the basis of prior studies
in a similar population, in which case the likelihood becomes
L =φN1{p0(1− φ− φλµ)}N3 [(1− p0)(1− φ) + φλµp0{1−H(τ)}]n0τ (φλp0µ)n1τ
×
n1τ￿
i=1
{H(bi)−H(ai)} (1.9)
To obtain the MLEs for (λ,φ, µ), we can again assume some parametric distribution for
G(·) and numerically maximize L. We refer to this maximum likelihood estimate of λ, λˆC ,
as Estimator C. An estimate of the covariance matrix of (λ,φ, µ) is provided by the sample
Fisher information corresponding to L in (1.9). In Web Appendix A, we derive the estimated
covariance matrix assuming that G(·) follows a Weilbull distribution, a flexible distribution
with support on positive numbers which is commonly-used in parametric survival modeling.
This estimator is consistent when p0 and the parametric assumption about G(·) are correctly
specified, regardless of length of follow-up τ . In Section 3, we examine the robustness of
this estimator to violation of assumptions about p0 and parametric distributions through
simulations. For estimators A, B, and C, a (1− α)100% confidence interval is given by
(λˆe−Z1−α/2sˆ/λˆ, λˆeZ1−α/2sˆ/λˆ) (1.10)
where sˆ is the square root of the diagonal element of the sample Fisher information corre-
sponding to λˆ. The confidence intervals in (1.10) are additive on the log scale. As suggested
by the associate editor, we also consider the use of profile likelihood confidence intervals in
Section 3.
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1.2.2 AF Estimator
Motivation
If we were to conduct a cohort study to estimate HIV incidence, i.e., the rate of transition
from State 1 to State 2 in our disease model, we could estimate the incidence rate by
# of events/person-years, where “number of events” refers to the number of transitions
from State 1 to State 2, and “person-years” refers to the cumulative time contributed by the
uninfected individuals in the cohort. Let T2 denote the time of entering State 3 and f2(·)
denotes its corresponding density function. Under the assumption of a constant infection
density, f(u) = f for u ∈ (t −W ∗, t), the probability of transition from State 1 to State 2
at time t, f(t), is related to the probability of transition from State 2 to State 3, f2(t). In
Appendix 3 we show that f(t) = f2(t)/p, which implies that
λ =
f
1− F (t) =
f2(t)
p{1− F (t)} . (1.11)
Assume f2(u) = f2, for u ∈ (t, t + τ). This is reasonable for a relatively small τ (e.g.,
12 weeks). From (1.11), we have λ = f2/[p{1 − F (t)}]. Suppose there is some minimum
time, say, τ ∗, spent in the recent infection state. That is, an infected individual will test
negative on the less-sensitive assay for at least τ ∗ from seroconversion. If the follow-up time
τ is chosen such that τ is less than this minimum time τ ∗, then G(τ) = 0. This implies that
P(Subject in State 1 at t | Subject in State 3 at t + τ) = 0. Hence, if we are interested in
observing the number of transitions into State 3 that occur in our sample between the time
of the cross-sectional testing, t, and the end of follow-up, t + τ , we only need to follow the
N2 patients who test positive on the sensitive test and negative on the less-sensitive test at
time t. The total number of transitions into State 3 during interval (t, t + τ) is given by
n1τ and f2 can be estimated by n1τ/(Nτ). This, combined with the fact that F (t) can be
estimated by (N −N1)/N Wang and Lagakos (2009), motivates us to consider the following
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estimator:
λˆ =
n1τ
N1pˆτ
, (1.12)
where
pˆ =
N3 + n1τ
N3 +N2
, (1.13)
as used in Estimator B. We note that pˆ will usually underestimate the true value of
p because the use of a shorter follow-up time means that n1τ will underestimate the true
number of transitions, n1, to State 3, had we been able to follow all N2 subjects found to be in
the recent state forW ∗. However, this will help to compensate for the fact that G(τ) may not
be strictly equal to 0 and hence n1τ could also underestimate the true number of transitions
to State 3 had we been able to follow all N1+N2 subjects “at risk” for transition into State 3
during the interval (t, t+ τ). We refer to this design as an augmented cross-sectional design
with abbreviated follow-up and the corresponding estimator as the AF estimator.
We note that this estimator has the same form as Estimator B, with the value µˆ = τ .
In fact, if τ is small, but we continue to use observed forward recurrence times for the n1τ
subjects to estimate the mean and the shape parameter (k) of a Weibull distribution G(·)
as described in Estimator B, we find through simulations that kˆ tends to be quite large and
µˆ ≈ τ .
Properties
In Appendix 4 we show that
E(λˆAF ) ≈ λµH(τ)
τ
1
1− pr(1−H(τ)) , (1.14)
where
pr =
λφµ
1− φ = P (recent infection | currently infected). (1.15)
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In a region with high prevalence and incidence, for example, (λ,φ, µ) = (.04, .7, .5),
we have pr < .05. As another example, a region with low prevalence and incidence with
(λ,φ, µ) = (.01, .92, .5) would yield pr < .06. Because pr is small and for small τ , H(τ) ≈
τh(0) = τ/µ, we have
E(λˆAF ) ≈ λµH(τ)
τ
1
1− pr{1−H(τ)} ≈
λµτh(0)
τ
=
λµτ
τµ
= λ. (1.16)
It is shown in Appendix 5 that
￿V ar{log(λˆAF )} ≈ 1
n1τ
. (1.17)
Thus, for early stopping times τ , a simple estimator and 95% CI could be calculated
by counting the number of transitions occurring during the τ follow-up time, with the point
estimate λˆAF given in (1.12) and confidence interval (λˆAF e
−1.96
￿
1
n1τ , λˆAF e
1.96
￿
1
n1τ ).
For the AF estimator to be expected to be close to the true incidence λ by a factor of
B, where B < (1− pr), i.e. Bλ ≤ E(λˆAF ) ≤ λ/B, we can choose τ such that (see Appendix
6)
τ ≤
￿ τ
0 1−G(x) dx
B[1− pr{1−H(τ)}] . (1.18)
Because [1 − pr{1 − H(τ)}] ≤ 1 and close to 1, a slightly more strict condition that will
guarantee the boundedness of the bias of the AF Estimator is
τ ≤
￿ τ
0 1−G(x) dx
B
. (1.19)
The above inequality highlights the dependence of the AF estimator on the assumption
of a relatively “flat” survival function 1 − G(x) : x ∈ (0, τ), i.e. some minimum amount
of time spent in State 2. A “perfect” test (W = µ, with probability 1) would result in
g(x) = 0 on the range (0,τ), and thus
￿ τ
0
1 − G(x) dx ≡ τ for any τ < µ. In practice, the
less-sensitive test does not have this “perfect” property. We find that the bias of the AF
estimator generally increases as the choice of stopping time τ increases. Because the width
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of the confidence interval based on the AF estimator is purely “event-driven”, it becomes
smaller with each additional observed transition. Therefore, a larger value of τ is associated
with increasing bias and decreasing variance. We have found through extensive simulations
that τ ≈ µ/2 is generally a good choice. Unless prior information is known about the value
of µ in the population of interest, we recommend the choice of τ = 12 weeks for use with
the AF estimator. We show in Section 3 that this leads to good performance in a variety of
settings.
In practice we do not know the exact distribution of sojourn times in a given popu-
lation. Rather, we may have some idea of mean window period µ and possibly coeﬃcient
of variation c = σ/µ. With a parametric assumption for the window period distribution
and (µ, c), we can calculate H(τ) and verify whether a 12-week AF estimator satisfies
Bλ ≤ E(λˆAF ) ≤ λ/B for a fixed B and a hypothetical value for pr, which is determined by
(λ,φ, µ) as in (1.15). In Figure 1.2(a), we provide the acceptable region, in terms of µ and
c, of the 12-week AF estimator for B = 0.9 and pr = .02, .04, .06, and .1. The boundaries
presented in this plot are generated by finding µmin;c that satisfies (1.18) for each fixed c.
We note that for µ1 < µ2, if (µ1,c) is in the acceptable region, then (µ2, c) must also be
in the acceptable region. Therefore, µmin;c provides a lower bound for all µ that satisfies
(1.18) for each c. We also find that the region which guarantees Bλ ≤ E(λˆAF ) ≤ λ/B when
the true distribution is Weibull is somewhat smaller than the corresponding region when
the true distribution is Lognormal. Because of this, we recommend using the reference
region based on the Weibull assumption when deciding whether to use the AF estimator,
in order to be conservative. An even more conservative boundary can be generated using
(1.19), which does not dependent on pr and hence does not require assumptions about
(φ,λ). Figure 1.2(b) shows the actual coverage levels of the nominal 95% confidence
intervals of the 12-week AF estimator for diﬀerent values of (c, µ), in a setting where
(N,λ,φ, p) = (6000, .03, .85, .99). We find that the actual coverage levels are close to the
nominal level for all parameter pairs that fall within the acceptable region corresponding to
B=.9, as shown in 1.2(a).
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Figure 1.2: Bias and Coverage of 12-week AF Estimator
Left: The 12-week AF Estimator will have acceptably small bias when (c,µ) lie above the line
associated with desired bound B=0.90
Right: Actual Coverage of Nominal 95% CI,
Coverage values obtained via simulation using (φ,λ, p) = (0.85, 0.03, 0.99) and G(·) ∼ Weibull
Design Considerations
Suppose that one wanted to conduct a study to estimate the incidence of HIV in a region
with some hypothesized parameter values (φ,λ, p), and had decided that the usage of the
AF estimator is both desirable and appropriate. Under this proposed design plan, biweekly
follow-up is not necessary, as only the total number of transitions occurring during the 12
weeks of follow-up is needed to produce this estimate of incidence, and could be obtained
via a single follow-up visit 12 weeks (τ=12/52 years) after the initial testing. This designed
study would require the administration of N (typically thousands) sensitive tests and N−N1
less-sensitive tests at time t, and a further N2 (typically < 100) less sensitive tests at time
t + τ . The precision of the AF estimator is closely tied with the number of transitions into
State 3 within 12 weeks (n1τ ). Below we show how to calculate the total sample needed
so that the ratio of the true incidence rate and the estimated rate, eZα/2
√
1/n1τ , is smaller
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than δ with (1− α)100% confidence. To achieve this, we require that n1τ ≥ {Zα/2/log(δ)}2.
For example, for δ = 2 and α = .05, we would need the number of transitions n1τ to be at
least 8. If we would like to achieve better precision, and let δ = 1.5, then we would require
n1τ ≥ 24.
Earlier we showed that the probability that a recently infected subject will transition
to State 3 within τ units of follow-up is φλpµH(τ) ≈ φλpτ for small τ . The sample size
N has the negative binomial distribution with number of failures r = n1τ and success rate
Ps = 1− φλpτ . Therefore, the sample size N required to obtain the observation of at least
n1τ failures with probability β is QNB(β, r = n1τ , Ps = 1 − φλpτ), where Q refers to the
quantile function of negative binomial distribution. A close approximation to this value can
be obtained by the following formula
N˜ =
(n1τ + Zβ ·√n1τ )(1− φλpτ)
φλpτ
. (1.20)
For example, in a high prevalence (φ = .75) and high incidence (λ = .04) population, if
we assume that p = .94, and would like to obtain at least 8 transitions into State 3 within
12 weeks with probability .9, then we would need to include at least N = 1799 subjects in
the cross-sectional sample. Suppose, instead, that we are in a setting with lower prevalence
(φ = .9) and incidence (λ = .02) and wish to observe at least 24 transitions with probability
.7. In this case, we would need N = 6713. Using the formula in (1.20) yields N˜=1775 and
6778, respectively, for the two settings discussed.
For a fixed sample size N and given parametric distribution G(·) and parameter
values (φ, λ, p), we can find the optimal follow-up time τ that minimizes the mean
squared error (MSE) of the AF Estimator numerically. For example, for the scenario
where φ = .75, λ = .04, and N = 1799, assuming that the true sojourn time dis-
tribution G(·) is Weibull with µ = .3 and c = .6, we find that the MSE is minimized
near τ = 13 weeks, with relatively little change in the MSE over the range τ ∈ (10, 15) weeks.
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1.2.3 Relationship Among Estimators
All of the estimators discussed in Sections 2.1 and 2.2 can be viewed as special cases of the
most general maximum likelihood estimator of incidence given τ units of follow-up time,
λˆ =
n1τ
N1pˆµˆHˆ(τ)
(1.21)
In general, it is not possible to estimate all of these quantities {p, µ,H(τ)} well without
external information or assumptions.
If we are in a setting where all apparent recent infections will eventually test positive on
the less-sensitive test, and that the concept of “long-term non-progressor” does not apply,
then p = 1, n1 = N2 and Hˆ(τ) = n1τ/N2. Therefore,
λˆ =
n1τ
N1pˆµˆHˆ(τ)
=
N2
N1µˆ
, (1.22)
which represents Estimator A. Alternatively, we could assume that the value of p is known
to be p0, and not equal to 1. In this case we need to estimate {µ,H(τ)}, and results in
Estimator C,
λˆ =
n1τ
N1p0µˆHˆ(τ)
. (1.23)
Rather than making assumptions about the value of p, one could instead make assump-
tions about G(·), and thus h(·), H(·), and µ. As discussed earlier in Wang and Lagakos
(2010), if we have some knowledge of W ∗, and choose τ ≥ W ∗, then Hˆ(τ) = 1 and n1 = n1τ ,
and
λˆ =
n1τ
N1pˆµˆHˆ(τ)
=
n1
N1pˆµˆ
, (1.24)
which represents Estimator B. If we do not have any knowledge of W ∗, or we are unable to
follow subjects for τ > W ∗ for logistical reasons, the AF estimator may oﬀer an attractive
alternative if (µ, c) falls within the acceptable region. The AF estimator works well when
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G(τ) ≈ 0. This results in Hˆ(τ) = τ/µˆ for small τ , and hence
λˆ =
n1τ
N1pˆµˆHˆ(τ)
=
n1τ
N1pˆτ
. (1.25)
1.3 Simulation Studies
We have discussed 4 diﬀerent estimators for estimating HIV incidence in an augmented cross-
sectional study with follow-up time τ . We performed an extensive simulation study to com-
pare their performance under a variety of situations. We assumed (N,λ,φ) = (6000, .02, .85)
throughout. We let p = 0.95 or 1. We considered Weibull and Lognormal for the underlying
distribution G(·) , with mean µ = .3, .4, or .5, and the coeﬃcient of variation c = .4, or .6.
The length of follow-up τ was taken to be 12, 24, or 52 weeks respectively. The frequency
of follow-up visits is assumed to be biweekly, except for the AF estimator, which only re-
quires a single follow-up visit at 12 weeks. In the case of Estimators A and C, we recorded
right-censored observations using b = 999 weeks as the upper bound for the transition time
of any patient whose transition is not observed during follow-up. For Estimator C, which
calls for a pre-specified value for p, p0 was taken to be .91, .95, or .99. For Estimators A,
B, and C, we assumed a Weibull distribution in our maximization procedure throughout the
paper because we found that using a Weibull distribution yields more robust results than
using a Lognormal distribution, as in Wang and Lagakos (2010). Results corresponding to
the usage of a Lognormal distribution in the maximization procedure are included in the
Web Tables 2 and 3. We also considered confidence intervals based on profile likelihood
methods. The width and coverage associated with profile likelihood confidence intervals are
comparable to those obtained based on (1.10) (see Web Table 4), although we noticed that
some computational diﬃculties arose when attempting to profile out the shape parameter of
the Weibull distribution, forcing us to impose a lower bound on this value.
When p = 1, although the actual coverage of the confidence intervals based on Estimator
A is close to the nominal level, we noticed that it tends to overestimate the true incidence rate
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Table 1.1: Simulation results for Estimators A and B, with N=6000, φ = .85 and λ=.02, and
assuming Weibull G(·). E(λˆ) and sd(λˆ) denote average and standard deviation of estimates
from 1000 simulated studies. E(sˆ) denotes average of likelihood-based estimates of the stan-
dard deviation from the 1000 experiments. Coverage denotes the proportion of experiments
in which the true λ is contained in the nominal 95% confidence interval, and Width refers
to the median width of the nominal 95% CI. Values in boldface represent scenarios where
conditions for this estimator are met.
Estimator A p=1 p=0.95
Weibull(µ=0.5,c=0.4) E(λˆ) sd(λˆ) E(sˆ) Cov. Width E(λˆ) sd(λˆ) E(sˆ) Cov. Width
τ=12 w, H(τ)=0.45 0.026 0.0137 0.0137 0.981 0.028 0.022 0.0078 0.0110 0.977 0.034
τ=24 w, H(τ)=0.80 0.022 0.0060 0.0059 0.962 0.021 0.023 0.0082 0.0099 0.959 0.035
τ=52 w, H(τ)=0.999 0.020 0.0047 0.0044 0.934 0.017 0.034 0.0128 0.0232 0.996 0.108
Weibull(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.64 0.026 0.0191 0.0175 0.971 0.038 0.023 0.0108 0.0169 0.962 0.074
τ=24 w, H(τ)=0.92 0.022 0.0101 0.0090 0.946 0.030 0.026 0.0127 0.0208 0.991 0.097
τ=52 w, H(τ) > 0.999 0.021 0.0077 0.0073 0.931 0.026 0.029 0.0190 0.0295 0.991 0.150
Lognorm(µ=0.5,c=0.4)
τ=12 w, H(τ)=0.46 0.026 0.0140 0.0126 0.977 0.026 0.022 0.0075 0.0107 0.978 0.031
τ=24 w, H(τ)=0.81 0.022 0.0058 0.0057 0.949 0.021 0.023 0.0082 0.0099 0.968 0.034
τ=52 w, H(τ)=0.992 0.022 0.0052 0.0053 0.940 0.020 0.035 0.0133 0.0247 0.997 0.117
Lognorm(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.67 0.026 0.0199 0.0158 0.982 0.037 0.023 0.0105 0.0165 0.968 0.072
τ=24 w, H(τ)=0.92 0.025 0.0108 0.0107 0.971 0.036 0.027 0.0129 0.0229 0.996 0.115
τ=52 w, H(τ)=0.995 0.024 0.0097 0.0099 0.957 0.036 0.030 0.0187 0.0308 0.992 0.173
Estimator B
Weibull(µ=0.5,c=0.4) E(λˆ) sd(λˆ) E(sˆ) Cov. Width E(λˆ) sd(λˆ) E(sˆ) Cov. Width
τ=12 w, H(τ)=0.45 0.022 0.0051 0.0059 0.960 0.023 0.022 0.0053 0.0061 0.963 0.024
τ=24 w, H(τ)=0.80 0.020 0.0037 0.0036 0.963 0.014 0.020 0.0038 0.0037 0.965 0.014
τ=52 w, H(τ)=0.999 0.020 0.0045 0.0043 0.933 0.016 0.020 0.0045 0.0044 0.933 0.017
Weibull(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.64 0.020 0.0060 0.0060 0.980 0.022 0.020 0.0064 0.0065 0.980 0.022
τ=24 w, H(τ)=0.92 0.019 0.0065 0.0054 0.861 0.018 0.019 0.0066 0.0057 0.842 0.018
τ=52 w, H(τ) > 0.999 0.021 0.0076 0.0072 0.932 0.026 0.021 0.0079 0.0075 0.910 0.026
Lognorm(µ=0.5,c=0.4)
τ=12 w, H(τ)=0.46 0.022 0.0051 0.0059 0.941 0.023 0.022 0.0054 0.0060 0.954 0.024
τ=24 w, H(τ)=0.81 0.020 0.0037 0.0037 0.952 0.014 0.020 0.0039 0.0038 0.962 0.014
τ=52 w, H(τ)=0.992 0.021 0.0048 0.0048 0.943 0.019 0.021 0.0048 0.0049 0.951 0.019
Lognorm(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.67 0.021 0.0060 0.0061 0.975 0.022 0.021 0.0061 0.0064 0.985 0.023
τ=24 w, H(τ)=0.92 0.020 0.0068 0.0061 0.897 0.021 0.020 0.0064 0.0060 0.911 0.021
τ=52 w, H(τ)=0.995 0.023 0.0085 0.0089 0.958 0.033 0.023 0.0081 0.0088 0.968 0.032
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in the settings we examined. For smaller value of τ , the variance associated with Estimator
A is quite large in relative to the true incidence rate. Because λ is bounded below at 0, large
variation in λˆ makes it more likely for us to obtain larger values of λˆ than smaller values of
λˆ, resulting in the average of λˆ to be biased high. We believe that this is a finite sample
problem. We also performed additional simulations with larger sample size, and noticed that
this overestimating phenomenon goes away. The precision of Estimator A improves for larger
values of τ . When p=.95, the bias associated with Estimator A increases with larger τ and
becomes substantial when τ = 52 weeks. Moreover, its precision also worsens substantially
as τ gets larger. These results suggest that Estimator A is very sensitive to assumptions
about p. Unless we are certain about p = 1, the use of Estimator A would best be avoided.
When H(τ) ≈ 1, Estimator B performs well as expected, for Weibull or Lognormal
G(·), as in Wang and Lagakos (2010). Its actual coverage level is generally near the nominal
level. When H(τ) < 1, we observe modest bias for Estimator B and the actual coverage
level can be substantially lower than the nominal level when τ = 24 weeks. Interestingly, we
find that Estimator B provides adequate coverage when τ = 12 weeks, and showed greater
precision than Estimator A in such scenarios. This phenomenon is closely related to the
good performance of the AF estimator and was also part of our motivation for considering
the AF estimator.
When p0 is correctly specified, Estimator C performs well in general, showing coverage
near the nominal level and precision improving with increasing values of τ . When the
hypothesized p0 is smaller than the true p, Estimator C behaves like Estimator B, maintaining
actual coverage greater than 92% for τ = 12 or τ = 52 weeks and can have the under-coverage
problem for τ = 24 weeks in some settings. When the hypothesized p0 is larger than the
true p, Estimator C behaves like Estimator A, and can lead to substantial bias and greater
variances.
As the follow-up time increases, the AF estimator becomes less variable yet more biased.
The 12-week AF Estimator performs well in all scenarios (see Table , with further simulation
Table 1.2: Simulation results for Estimator C, with N=6,000, φ = .85 and λ=0.02, and
assuming Weibull G(·). E(λˆ) and sd(λˆ) denote average and standard deviation of estimates
from 1000 simulated studies. E(sˆ) denotes average of likelihood-based estimates of the stan-
dard deviation from the 1000 simulations. Coverage denotes the proportion of simulations
in which the true λ is contained in the nominal 95% confidence interval, and Width refers
to the median width of the nominal 95% CI. Values in boldface represent scenarios where
conditions for this estimator are met.
Estimator C p=1 p=0.95
Weibull(µ=0.5,c=0.4) E(λˆ) sd(λˆ) E(sˆ) Cov. Width E(λˆ) sd(λˆ) E(sˆ) Cov. Width
po=0.95
τ=12 w, H(τ)=0.45 0.022 0.0056 0.0060 0.971 0.022 0.025 0.0157 0.0138 0.992 0.028
τ=24 w, H(τ)=0.80 0.019 0.0037 0.0036 0.960 0.013 0.022 0.0075 0.0062 0.963 0.020
τ=52 w, H(τ)=0.999 0.020 0.0043 0.0042 0.936 0.016 0.021 0.0060 0.0051 0.927 0.018
po=0.99
τ=12 w, H(τ)=0.45 0.025 0.0149 0.0124 0.994 0.027 0.023 0.0090 0.0121 0.998 0.031
τ=24 w, H(τ)=0.80 0.020 0.0043 0.0042 0.964 0.014 0.023 0.0085 0.0100 0.975 0.034
τ=52 w, H(τ)=0.999 0.020 0.0043 0.0042 0.936 0.016 0.038 0.0152 0.0263 0.989 0.121
Weibull(µ=0.3,c=0.6)
po=0.95
τ=12 w, H(τ)=0.64 0.020 0.0071 0.0064 0.984 0.021 0.027 0.0228 0.0210 0.989 0.036
τ=24 w, H(τ)=0.92 0.019 0.0066 0.0054 0.843 0.018 0.024 0.0161 0.0132 0.932 0.030
τ=52 w, H(τ) > 0.999 0.021 0.0077 0.0073 0.924 0.027 0.022 0.0150 0.0099 0.926 0.027
po=0.99
τ=12 w, H(τ)=0.64 0.023 0.0165 0.0107 0.981 0.023 0.025 0.0131 0.0198 0.999 0.078
τ=24 w, H(τ)=0.92 0.019 0.0067 0.0056 0.850 0.019 0.029 0.0166 0.0251 0.990 0.116
τ=52 w, H(τ) > 0.999 0.021 0.0077 0.0073 0.924 0.027 0.042 0.0302 0.0505 0.999 0.296
Lognorm(µ=0.5,c=0.4)
po=0.95
τ=12 w, H(τ)=0.46 0.023 0.0053 0.0059 0.950 0.022 0.026 0.0133 0.0136 0.985 0.027
τ=24 w, H(τ)=0.81 0.020 0.0038 0.0037 0.955 0.014 0.022 0.0059 0.0058 0.969 0.019
τ=52 w, H(τ)=0.992 0.021 0.0046 0.0048 0.954 0.019 0.022 0.0055 0.0055 0.948 0.020
po=0.99
τ=12 w, H(τ)=0.46 0.025 0.0120 0.0110 0.978 0.025 0.023 0.0088 0.0120 0.996 0.031
τ=24 w, H(τ)=0.81 0.021 0.0044 0.0042 0.950 0.015 0.024 0.0087 0.0099 0.994 0.033
τ=52 w, H(τ)=0.992 0.021 0.0046 0.0048 0.954 0.019 0.038 0.0157 0.0279 0.988 0.132
Lognorm(µ=0.3,c=0.6)
po=0.95
τ=12 w, H(τ)=0.67 0.021 0.0059 0.0059 0.972 0.022 0.026 0.0192 0.0170 0.992 0.034
τ=24 w, H(τ)=0.92 0.020 0.0064 0.0061 0.901 0.022 0.025 0.0139 0.0123 0.962 0.033
τ=52 w, H(τ)=0.995 0.023 0.0080 0.0088 0.965 0.033 0.025 0.0143 0.0117 0.960 0.035
po=0.99
τ=12 w, H(τ)=0.67 0.022 0.0094 0.0081 0.971 0.023 0.025 0.0137 0.0194 1.000 0.071
τ=24 w, H(τ)=0.92 0.020 0.0066 0.0063 0.910 0.023 0.031 0.0167 0.0284 1.000 0.144
τ=52 w, H(τ)=0.995 0.023 0.0080 0.0088 0.965 0.033 0.046 0.0357 0.0573 0.999 0.351
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results in Web Table 5) within the acceptable region outlined in 1.2(a). For these situations,
it shows greater precision than all other estimators with τ = 12 weeks. For settings in the
non-acceptable region, the use of the AF estimator should be avoided. For example, when
(µ, c) = (.3, .8), the actual coverage level of the AF estimator drops to 85%.
Table 1.3: Simulation results for the AF Estimator, with N=6000, φ = .85 and λ=0.02.
E(λˆ) and sd(λˆ) denote average and standard deviation of estimates from 1,000 simulated
studies. E(sˆ) denotes average of likelihood-based estimates of the standard deviation from
the 1,000 simulations. Coverage denotes the proportion of simulations in which the true λ
is contained in the nominal 95% confidence interval, and Width refers to the median width
of the nominal 95% CI.
AF Estimator p=1 p=0.95
Weibull(µ=0.5,c=0.4) E(λˆ) sd(λˆ) E(sˆ) Cov. Width E(λˆ) sd(λˆ) E(sˆ) Cov. Width
τ=12 w, H(τ)=0.45 0.020 0.0043 0.0042 0.945 0.017 0.021 0.0042 0.0043 0.951 0.018
τ=24 w, H(τ)=0.80 0.018 0.0028 0.0027 0.886 0.011 0.018 0.0028 0.0028 0.887 0.011
τ=52 w, H(τ)=0.999 0.010 0.0015 0.0014 0.000 0.006 0.010 0.0015 0.0014 0.000 0.006
Weibull(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.64 0.017 0.0039 0.0038 0.915 0.015 0.017 0.0039 0.0039 0.923 0.016
τ=24 w, H(τ)=0.92 0.012 0.0022 0.0023 0.158 0.009 0.012 0.0024 0.0023 0.161 0.009
τ=52 w, H(τ) > 0.999 0.006 0.0011 0.0011 0.000 0.004 0.006 0.0012 0.0011 0.000 0.004
Lognorm(µ=0.5,c=0.4)
τ=12 w, H(τ)=0.46 0.021 0.0041 0.0042 0.952 0.017 0.021 0.0045 0.0043 0.935 0.017
τ=24 w, H(τ)=0.81 0.018 0.0028 0.0027 0.887 0.011 0.018 0.0028 0.0028 0.899 0.011
τ=52 w, H(τ)=0.992 0.010 0.0014 0.0014 0.000 0.006 0.010 0.0014 0.0014 0.000 0.006
Lognorm(µ=0.3,c=0.6)
τ=12 w, H(τ)=0.67 0.018 0.0039 0.0039 0.930 0.016 0.018 0.0040 0.0040 0.944 0.016
τ=24 w, H(τ)=0.92 0.012 0.0023 0.0022 0.170 0.009 0.012 0.0023 0.0023 0.180 0.009
τ=52 w, H(τ)=0.995 0.006 0.0011 0.0011 0.000 0.004 0.006 0.0011 0.0011 0.000 0.004
Illustrative Examples Because data following such an augmented cross-sectional design
do not yet exist, we chose 2 of our simulated data sets from the scenario with Weibull
G(·) and (µ, c) = (.5, .4) for illustration. The first data set was generated with p=1,
indicating that the conditions for Estimator A were met for any choice of τ , while the
assumptions underlying Estimator B were approximately satisfied (H(τ) > .99) for τ ≥
44 weeks. In Figure 1.3(a), we see that both incidence estimators have point estimates
near the true incidence value and confidence intervals containing the true value, for any
choice of τ . Furthermore, we see that the width of the confidence interval of Estimator B
is comparable to that of Estimator A for most values of τ . The AF Estimator is shown in
gray and yields results similar to those of the other estimators for smaller values of τ . The
second data set was generated with p=.95, indicating that the conditions for Estimator
A were never met in this setting. In this example (Fig. 1.3(b)), we see that Estimator A
suﬀers greatly in its precision as τ increases. The 12-week AF Estimator yields results simi-
lar to those of Estimator B for τ = 12 weeks, though with a somewhat smaller interval width.
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Figure 1.3: Point estimates and 95% confidence intervals for the incidence rate at diﬀerent
stopping times τ . The data sets were chosen from the simulation study described in Section
3.
Black Dashed: Estimator A, Black Solid: Estimator B, Gray Dotted: AF Estimator
G(·) ∼ Weibull, (µ,c) = (.5,.4)
1.4 Discussion
In this paper, we assess how the performance of various estimators are aﬀected by length of
follow-up τ and/or assumptions about the size of the “long-term non-progressor” population.
We found that Estimator A, which assumes p = 1, can result in substantial bias and great
loss of precision if the true p is less than 1. This pattern also holds for Estimator C when
we overestimate the true p. When p is correctly specified, both Estimator A and Estimator
C work well regardless of length of follow-up. However, p is often not known in practice and
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is expected to vary according to the type of less-sensitive test and population of interest.
Estimator B does not require prior knowledge of p, but instead requires length of follow-up
to be long enough so that subjects who have not become reactive to the less-sensitive test at
the end of the follow-up will remain non-reactive permanently. We found that Estimator B
is robust to modest violation of this assumption. Interestingly, when we apply Estimator B
with very short follow-up, say, 12 weeks, it works reasonably well and has led us to consider
a new HIV incidence estimator based on an abbreviated follow-up time, the AF estimator.
The AF estimator has the benefit of not requiring any specific external estimate of
p or µ, as well as substantially shortening the amount of follow-up compared to earlier
augmented cross-sectional designs without substantial loss of precision. The AF estimator
requires rather general assumptions about the distribution of the time spent in the “recent
infection” state, and its use will become more feasible as more information becomes available
characterizing these distributions associated with particular less-sensitive tests in diﬀerent
populations. We note that the length of follow-up τ may be chosen to be somewhat smaller
than 12 weeks, which will further relax the distributional assumptions necessary for the AF
estimator. However, the sample size will need to be increased accordingly, as shown in (1.20),
to maintain desired precision. Since the precision of the AF estimator is dependent solely
on the observed number of transitions into State 3, it is recommended that all N2 patients
be retested at the 12-week follow-up visit. However, if it is only feasible to follow a random
subsample of size n2 < N2 of these patients, the AF estimator can be easily adapted by
replacing the value n1τ with n1τ ·N2/n2 in (1.12) and (1.13). The procedure for calculating
the confidence intervals remains unchanged.
The AF estimator, despite its attractive properties, is biased and therefore currently can
only serve as a crude estimator when resources are limited. When possible, we recommend
the use of Estimator B proposed in Wang and Lagakos (2010) and to follow subjects for a
reasonably long period of time. To facilitate the implementation of the augmented cross-
sectional design and the use of Estimator B, it would be helpful to provide guidance on
several design issues such as sample size of the cross-sectional sample, number of subjects
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needed to be followed and visit frequency. Because an explicit variance formula for µˆ is not
readily attainable, we do not have a formula for sample size yet. Using simulations and a grid
search, we can calculate sample sizes needed to estimate incidence in a population of interest.
For example, for one of the settings we examined in 2.2.3, when (φ,λ, p) = (.75, .04, .94), if
we assume the underlying distribution for the window period is Weibull with µ = .5 and
c = .3, we would need about 2200 subjects in the cross-sectional sample and to follow all
subjects found to be in ‘recent state’ for about 1 year, in order for δ = 2 with probability
80%. Interestingly, we found that the changes in the required sample size were negligible
when we relaxed a 2-week visit schedule to a 6-week visit schedule. Whether this holds true
in general warrants further research.
We emphasize the importance of quantifying p. With correct knowledge of p, Estimator
A or Estimator C would work well with shorter follow-up than that required by Estimator
B. Furthermore, if p is known, and it is possible to devise a less-sensitive test which has the
property that subjects will not become reactive for a minimum period of time τ ∗, then the
AF estimator would be unbiased with τ < τ ∗.
We investigated the implementation of a fully Bayesian model to address the problem
at hand with what we consider to be fairly vague priors (Web Appendix B). The results
are included in Web Table 5. When the true parameters lie well within the interior of the
prior distributions, the Bayesian method produces credible intervals with width narrower
than those obtained from Estimators A, B, and C, and comparable to those from the AF
estimator. However, the Bayesian method is seen to have under-coverage problems when the
true parameters are close to the boundary of their prior distributions. For example, when
true µ=.3 years and the prior distribution was chosen as Uniform on the interval from .25
years to 1.5 years, even though the prior distribution has non-negligible mass near the true
value, the posterior distribution is not symmetric around the true value, due to the truncation
at .25 years. The strong negative correlation between λˆ and µˆ can result in λˆ being biased
low. Thus the corresponding 95% credible interval may not have the nominal coverage. It
would also be useful to investigate whether the EM algorithm can be used eﬀectively in the
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calculation of Estimator C, by iteratively assigning the n0τ patients to either State 2 or State
4, based on the estimated parameter values at each step, then re-estimating the parameter
values by maximizing the updated likelihood function, based on the state assignments.
Recent evidence suggests that use of antiretroviral treatments (ART) can aﬀect the
results of less-sensitive diagnostic tests (Marinda et al., 2010). For this reason, it is critical
that patients’ ART use be documented. One suggestion is to exclude patients with known
ART use from the initial cross-sectional sample (Mcdougal et al., 2006), though this could
potentially impact the validity of the resulting prevalence estimate if ART use is common
in the study region. Suppose that some number of the N2 infected patients in the cross-
sectional survey who test negative on the less-sensitive test are known to be receiving ART.
Assuming that these patients’ test results do not change during the follow-up period, all
n∗ patients could be reassigned to State 3 or “non-recent infection”. An alternative would
be to reassign pˆn∗ of these patients to State 3, while keeping the remaining (1 − pˆ)n∗ in
State 4. Both methods could be employed and the resulting estimates compared as a sort
of sensitivity analysis. The assumption being made here is that the population of patients
currently receiving ART at a given time is likely to be comprised of a disproportionately
smaller percentage of “long-term non-progressors” than the overall infected population.
Supplementary Materials
Web Appendices and Tables referenced in Sections 1.2.1, 1.2.2, 1.3, and 1.4 are available
under the Paper Information link at the Biometrics website http://www.biometrics.tibs.
org.
25
Acknowledgements
We thank the editor, an associate editor and two referees for their comments, which improved
the paper. This research was supported by grants R37 AI24643 and T32 AI007358 from the
National Institutes of Health.
1.5 Appendix
1.5.1 Appendix 1: Likelihood Function for Model in Section 1.2.1
The state prevalence probabilities at time t are given by (Balasubramanian and Lagakos,
2010; Wang and Lagakos, 2009)
π1(t)
def
= P (in State 1 at time t) = 1− F (t) = φ, (1.26)
π2(t)
def
= P (in State 2 at time t) = pφλµ, (1.27)
π3(t)
def
= P (in State 3 at time t) = p(1− φ− φλµ), (1.28)
π4(t)
def
= P (in State 4 at time t) = (1− p)(1− φ). (1.29)
The cumulative distribution function of X, for x > 0, conditional on t, is (Wang and
Lagakos, 2010):
H(x | t) =
￿ x
0
1−G(v)
µ
dv. (1.30)
In our setting, only those who are observed to test positive on the less-sensitive test
within the τ units of follow-up (i.e. those with forward recurrence time X < τ), will be
determined to definitely be in State 2 at time t. Thus the probability of actually being in
State 2 and being observed to transition to State 3 during the follow-up time is π2H(τ | t) =
φλpµH(τ | t). The probability of actually being in State 2 at the time of the cross-sectional
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sample, but not being observed to transition into State 3 during the follow-up period is then
π2{1−H(τ | t)} = φλpµ{1−H(τ | t)}. (1.31)
The additional information from the interval-censored forward recurrence times of those
patients determined to be in State 2 is
P (a < x < b|x < τ) = H(b | t)−H(a | t)
H(τ | t) . (1.32)
1.5.2 Appendix 2: Probability Limit of λˆB
λˆB =
n1τ
N1pˆτ µˆτ
, where pˆτ =
N3+n1τ
N3+n1τ+n0τ
= N3+n1τN3+N2 . Let µτ be the probability limit of µˆτ . From
n1τ
N
p→ pφλµH(τ), N1
N
p→ φ, N2 +N3
N
p→ (1− φ), and N3
N
p→ p(1− φ− φλµ), (1.33)
we have
pˆτ =
(N3 + n1τ )/N
(N3 +N2)/N
p→ p(1− φ− φλµ) + pφλµH(τ)
1− φ =
p[1− φ− φλµ{1−H(τ)}]
1− φ , (1.34)
and
λˆB =
n1τ/N
N1/Npˆτ µˆτ
p→ pφλµH(τ)
φp[1−φ−φλµ{1−H(τ)}]1−φ µτ
= λ
µ
µτ
(1− φ)H(τ)
[1− φ− φλµ{1−H(τ)}] . (1.35)
1.5.3 Appendix 3: Relationship of f(t) and f2(t)
f2(t) = P (transition from State 2 to State 3 at time t)
=
￿
P (infected at time t− u)× P (in subgroup that will transition to State 3)
× P (sojourn time in State 2 = u|in subgroup that will transition to State 3) du.
(1.36)
Under the assumption that f(u) is constant over u ∈ (t−W ∗, t),
f2(t) =
￿ W ∗
u=0
f(t− u) · p · g(u)du = f · p
￿ W ∗
u=0
g(u)du = f · p ·G(W ∗) = pf (1.37)
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1.5.4 Appendix 4: Expectation of AF Estimator
Recall λˆAF =
n1τ
N1pˆτ τ
= n1τ (N3+N2)N1τ(N3+n1τ ) =
N3+N2
N1
n1τ
N3+n1τ
1
τ , therefore,
E(λˆAF ) = E(
N3 +N2
N1
n1τ
N3 + n1τ
1
τ
) =
1
τ
E(
N3 +N2
N1
n1τ
N3 + n1τ
). (1.38)
Because (N1, n1τ , n0τ , N3) ∼ Multinomial(N ; p1, p2, p3, p4), we have
n1τ |(N1, n0τ ) ∼ Binomial(N −N1 − n0τ , p2
1− p1 − p3 ). (1.39)
Now, we want to show E(XY) = E(X) E(Y), where X = N3+N2N1 , Y =
n1τ
N3+n1τ
.
E(Y ) = E{E(Y |N1, n0τ ))} = E{E( n1τ
n1τ +N3
|N1, n0τ )} = E{ 1
n1τ +N3
E(n1τ |N1, n0τ )}
= E(
1
n1τ +N3
(n1τ +N3)p2
p2 + p4
) = E(
p2
p2 + p4
) =
p2
p2 + p4
(1.40)
and
E(Y |X) = E{E(Y |N1, n0τ )|X} = E( p2
p2 + p4
|X) = p2
p2 + p4
(1.41)
Because E(Y |X) = E(Y )⇒ E(XY ) = E(X)E(Y ),
so E(λˆAF ) =
1
τ
E(
N3 +N2
N1
)E(
n1τ
N3 + n1τ
)
≈ 1
τ
1− φ
φ
pλφµH(τ)
1− φ− pφλµ{1−H(τ)}
=
λµH(τ)
τ
1
1− pr{1−H(τ)} (1.42)
where pr =
λφµ
1− φ = P (recent infection|currently infected). (1.43)
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1.5.5 Appendix 5: Approximate Variance of AF Estimator
Using (1.12) and (1.13), we have
log(λˆAF ) = log(
N2 +N3
N1
) + log(
n1τ
N3 + n1τ
)− log(τ) (1.44)
Because the two terms are shown to be independent in Appendix 4, this leads to
V ar{log(λˆAF )} = V ar{log(N2 +N3
N1
)}+ V ar{log( n1τ
N3 + n1τ
)} (1.45)
Note that log{(N2 + N3)/N1} is the log odds of HIV prevalence, its variance can be con-
sistently estimated by 1/N1 + 1/(N2 + N3) (Woolf et al., 1955). Similarly, by applica-
tion of the δ-method and common variance formula for sample proportion, the variance of
log{n1τ/(N3 + n1τ )} can be approximated by N3/{n1τ (N3 + n1τ )}. Therefore,
￿V ar{log(λˆAF )} ≈ 1
N1
+
1
N2 +N3
+
N3
n1τ (N3 + n1τ )
≈ 1
n1τ
, (1.46)
where the last approximation follows from that N1 and N3 are usually much larger than n1τ ,
and therefore 1/N1 and 1/(N2+N3) are negligible compared to 1/n1τ , and N3/(N3+n1τ ) ≈ 1.
1.5.6 Appendix 6: Bounding the Bias of AF Estimator
Suppose we wish to bound the bias of the AF Estimator, such that the expected value
of the AF Estimator is close to the true incidence rate, to within a factor of B. That is,
Bλ ≤ E(λˆAF ) ≤ λ/B. Using (1.42), after some simplification we have
Bτ [1− pr{1−H(τ)}] ≤
￿ τ
0
1−G(x) dx ≤ τ
B
[1− pr{1−H(τ)}] (1.47)
where pr is defined in (1.43).
If the desired bound B is chosen such that B ≤ (1 − pr), then the second inequality is
always satisfied, because τ ≤ τ [1− pr{1−H(τ)}]/B and
￿ τ
0
1−G(x) dx ≤ τ since G(·) ≥ 0
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always. In this case, we only need to consider the first inequality, which can be expressed as
τ ≤
￿ τ
0 1−G(x) dx
B[1− pr{1−H(τ)}] . (1.48)
If a tighter bound B is desired, such that B > (1 − pr), we must also satisfy the second
inequality, which can be expressed as
τ ≥ B
￿ τ
0 1−G(x)dx
[1− pr{1−H(τ)}] . (1.49)
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2.1 Introduction
Consider a randomized, comparative clinical trial in which a treatment is assessed against a
control with respect to their risk-benefit profiles. Conventionally, a single treatment contrast
is utilized to assess an overall treatment diﬀerence with respect to eﬃcacy, in addition to a
global measure of toxicity, over a rather heterogeneous population. Unfortunately, the result-
ing inference about these two measures are rather diﬃcult to interpret in clinical practice.
Making patient-specific decisions based on estimated population-averaged eﬀects can lead
to sub-optimal patient care (Kent and Hayward, 2007). A positive (negative) trial based on
these two overall measures does not mean that every future patient should (should not) be
treated by the new treatment. To bring the clinical trial results to the patient’s bedside,
we may utilize the patient’s characteristics which relate to the response variable to perform
so-called personalized or stratified medicine. Unfortunately, the typical ad hoc subgroup
analysis of clinical studies is not credible (Wang et al., 2007). Moreover, such subgroup
analysis is often conducted by investigating the eﬀect of only a single predictor at a time
and therefore may not be eﬀective in identifying patients who would benefit from the new
treatment.
In this paper, we present a systematic approach to nonparametrically estimate subject-
specific treatment diﬀerences from a risk-benefit perspective. To address the issue of risk-
benefit assessment, we propose categorizing each patient into one of several ordered categories
at a given follow-up time, more thoroughly reflecting the patient’s treatment experience.
That is, for each study subject, the observations are times to events that could be used define
the eﬃcacy and toxicity of the treatment, which are then used to categorize a patient’s overall
clinical outcome. In the event of censoring of one or more of these event outcomes, we use
inverse-probability weighting to obtain consistent estimates of the associated probabilities.
In order to assess these treatment eﬀects nonparametrically from a personalized medicine
perspective, we use a training data set to first build a parametric univariate scoring system
using baseline variables and then stratify subjects in the target data set accordingly. We then
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estimate the treatment eﬀects nonparametrically with respect to the risk-benefit categories.
When there is a single baseline covariate involved, Bonetti et al. (2000); Song and Pepe
(2004) and Bonetti and Gelber (2004) have proposed novel statistical procedures for iden-
tifying a subgroup of patients who would benefit from the new treatment with respect to
eﬃcacy. A recent paper by Janes et al. (2011), which is based on previous work by Pepe
(2004), Huang et al. (2007), and Pepe et al. (2008), provides practical guidelines for measur-
ing the performance of individual markers for treatment selection. By incorporating more
than one baseline covariate at a time, our approach is similar in spirit to Cai et al. (2011)
and Li et al. (2011). However, they both used a single study to create a scoring system by
fitting a prespecified model without model evaluation or variable selection. They then use
the same data set to make inferences for either the treatment diﬀerence without considering
multiple within-patient outcomes or for risk predictions for a single treatment group only.
2.2 Data
2.2.1 Target Data
Our data set of interest comes from a recent clinical trial, “Beta-Blocker Evaluation of Sur-
vival Trial” (BEST), which compared a beta-blocker to placebo in patients with heart failure
(HF), with a primary endpoint of all-cause mortality. In this trial, other monitored patient
outcomes included timing of hospitalizations, with cause of each hospitalization recorded as
being due to the patient’s chronic heart failure or for other reasons, and all deaths were
adjudicated as being due to cardiovascular causes (CV death), or otherwise (non-CV death)
(Beta-Blocker Evaluation of Survival Trial Investigators, 2001). Note that in the BEST
trial, the non-fatal event times were not censored by other non-fatal event times. This trial
enrolled 2708 patients and is of particular interest because of the observed marginally signif-
icant treatment eﬀect (p=0.10), with an estimated hazard ratio of 0.90 (0.78, 1.02) for the
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eﬀect of treatment on mortality, the primary endpoint of the study. This result stands in
contrast to other studies of beta-blockers in patients with heart failure which were conducted
around the same time, each of which showed highly significant beneficial treatment eﬀects
with hazard ratios ≤ 0.67 and p-values ≤ 0.001 (Domanski et al., 2003).
2.2.2 Training Data
The usage of an independent training data set is crucial for multiple reasons. Primarily, the
proposed training/validation approach allows one to avoid the nontrivial “self-serving” bias
that can result from performing the model-building and variable selection process, creating
the score, stratifying subjects, and estimating subject-specific treatment diﬀerences all within
the same data set. Practically, the medical literature contains multiple examples of beta-
blocker trials which have suggested diﬀerential treatment eﬀects according to various baseline
covariates, none of which were able to be confirmed in subsequent trials. Furthermore, it has
been noted that the validity of subgroup findings is strengthened when able to be validated
prospectively (Friedman et al., 2010). Finally, since formal evaluations of new drugs or
devices usually require two well-conducted studies, it is often feasible that a trial sponsor
has access to existing trial data that is directly relevant to the study of interest. Because we
have access to only this particular trial, we instead mimic a hypothetical interim analysis
which could have been conducted by analyzing only the first 900 patients (∼ 33% of total
enrollment).
We used the outcome data (mortality and hospitalizations) from these early patients,
along with 16 available patient-level covariates to derive the parametric scoring systems
which would be used to stratify the remaining patients in the BEST study.
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2.2.3 Patient Outcome Categories
In order to both develop the scoring systems in the training data set and evaluate the patient
outcomes in the validation set, a classification system is needed describe each patient’s status
at a fixed followup time t0. A simple and intuitive classification scheme, as described below,
would involve five mutually exclusive and exhaustive categories, depending on which, if any,
events have been experienced by a patient prior to t0. This classification scheme is designed
to account for events whose reduction represents an anticipated “benefit” of treatment (i.e.
CV hospitalization, CV death), as well as events which may plausibly occur more frequently
as a result of treatment, and are therefore considered potential treatment “risks” (i.e. non-
CV hospitalization, non-CV death).
For patient i receiving treatment j, let T(1)ij denote a patient’s time to first non-CV
hospitalization, T(2)ij denote the time to the first CV-related hospitalization, and T(3)ij denote
the time to death, where i = 1, ..., nj; j = 1, 2. Furthermore, let δij = 1 if a patient’s death is
classified as being CV-related, and δij = 0 otherwise. In the following analysis, we will target
the joint distribution of {(T(1)j, T(2)j, T(3)j, δj), j = 1, 2} for patients with given parametric
score, which is needed for risk-benefit analysis on a personalized level. This novel approach
is diﬀerent from the conventional risk-benefit analysis, whose main objective is to separately
characterize distribution of (T(3)j, δj), as well as the marginal distributions of T(1)j and T(2)j
over the entire population. To this end, let us define a patient’s classification at t0 by ￿(t0)ij,
where
• ￿(t0) = 0 if t0 < (T(1) ∧ T(2) ∧ T(3)) (i.e., patient is “alive and healthy”)
• ￿(t0) = 1 if T(1) ≤ t0 < (T(2) ∧ T(3)) (i.e., patient is “alive and hospitalized without
worsening HF”)
• ￿(t0) = 2 if T(2) ≤ t0 < T(3) (i.e., patient is “alive with worsening HF”)
• ￿(t0) = 3 if T(3) ≤ t0, δ = 0 (i.e., patient experienced “non-CV death”)
• ￿(t0) = 4 if T(3) ≤ t0, δ = 1 (i.e., patient experienced “CV death”)
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This classification is obviously defined by T(1)ij, T(2)ij, T(3)ij, and δij jointly and its conditional
distributions for patients with given parametric score in the treatment as well as control
groups may guide us to make optimal treatment recommendations for this group of patients.
For clarity of notation, we will assume t0 is fixed and will henceforth denote classification
status using ￿ instead.
2.3 Building a Scoring System via the Training Data
Set
To begin, we use the BEST training data set to build a scoring system using the patients’
baseline characteristics with respect to the above ordinal outcome categories. In order to
use nonparametric methods in the evaluation stage which estimate the expected treatment
eﬀects over a univariate scoring system, the goal of the first stage of our procedure is to reduce
the multivariate covariate vector U to a single covariate S = f(U) which will be eﬀective in
grouping patients who would experience similar treatment eﬀects. Thus, even though we are
interested in assessing the eﬀect of treatment on more than one outcome, we must construct
a single score so that each patient i is associated with a single covariate value Si. Specifically,
for this training set, each subject was assigned to a particular treatment j, where j = 1, 2.
Let Uj be the vector of baseline covariates, including the treatment indicator τj with τj = 1 in
the treated group, and 0 otherwise. Let Cj be the censoring variable, which is assumed to be
independent of Uj and all Tj. Furthermore, let X(1)j = min(T(1)j, Cj), X(2)j = min(T(2)j, Cj),
and X(3)j = min(T(3)j, Cj) and {∆(r)j, r = 1, 2, 3} be the indicator function, which is one
if T(r)j ≤ Cj. The data consist of {(X(1)ij, X(2)ij, X(3)ij,∆(1)ij,∆(2)ij,∆(3)ij, δij, Uij)￿, i =
1, · · · , nj}, nj independent copies of {(X(1)j, X(2)j, X(3)j,∆(1)j,∆(2)j,∆(3)j, δj, Uj)￿, j = 1, 2}.
Now, suppose that we are interested in estimating the t0-year outcome probabilities
πjk(U), j = 1, 2, where
πjk(U) = pr(￿j = k|U) (2.1)
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for a pre-specified time point t0. To obtain estimates for πjk(U), one may use an ordinal
regression working model of the following form
g(γjk(Uij)) = αk − β￿Zij − τij(β∗￿Zij) (2.2)
where γjk =
￿k
l=0 πjl is the cumulative probability of a patient in treatment group j being
classified into outcome category ￿ ≤ k, Zij is a given function of Uij, g(·) is a given monotone
function, and α, βj and β∗j are unknown vectors of parameters, with βj and β
∗
j corresponding
to the main eﬀects and treatment interaction eﬀects, respectively, of the covariates Z on
patient outcome status. Noting that a patient’s outcome status is observable only when
min(T(3), t0) ≤ C, the parameter vectors above may be estimated by applying inverse proba-
bility of censoring weights and maximizing the standard weighted multinomial log-likelihood
function
￿
ij
wij
Gˆj(X(3)ij ∧ t0)
{
4￿
k=0
I(￿ij = k)log(πjk(Uij))}, (2.3)
with respect to (α, β, β∗) where πjk = f(α, β, β∗, Zij, τij) via (2.2), wij = I(X(3)ij ≤
t0)∆ij+I(X(3)ij > t0), I(·) is the indicator function, and Gˆj(·) is the Kaplan-Meier estimator
for Gj(·), the survival function of the censoring variable for the jth group. (Zheng et al.,
2006; Uno et al., 2007a; Li et al., 2011).
Under some mild conditions, the resulting estimators (αˆ, βˆ, βˆ∗) converge to a finite con-
stant vector as n → ∞ even when the model (2.2) is not correctly specified (Uno et al.,
2007a).
Note that one may repeatedly utilize (2.2) and (3.5) with various Z and g(·) via, for
instance, a standard stepwise regression procedure with U , to obtain final estimates πˆjk(U).
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2.3.1 Evaluation of Working Models
Since many variable selection procedures and link functions can be considered as candidates
for estimating πjk(·), j = 1, 2, it is important to formally evaluate their relative merits.
To this end, we first note that the adequacy of such ordinal regression models for t0-year
outcomes can be quantified by the cross-validated log-likelihood, where a larger log-likelihood
suggests a better model fit. We use a repeated random cross-validation procedure, in each
iteration randomly dividing the entire training data set into two mutually exclusive subsets,
B and H, with the “model building set” B comprising approximately 80% of the full training
set. For each model building set and for a given link function and variable selection procedure,
we can construct a model, using only patients in B to estimate πjk(U), yielding predicted
probabilities for the patients in the holdout set H, with predictions given by πˆjk(Uij). The
cross-validated log-likelihood, adjusted for censoring, is
￿
(i,j)∈H
wij
Gˆj(X(3)ij ∧ t0)
{
4￿
k=0
I(￿ij = k)log(πˆjk(Uij)}, (2.4)
We may further examine the adequacy of a given model in predicting outcomes for a
specific treatment group by summing only over patients in a particular treatment group j.
We repeatedly split the training data set M times. For each m, and for each modeling
procedure, we obtain an estimate of the group-specific log-likelihood value denoted by ￿L(m)j ,
and the overall log-likelihood ￿L(m) = ￿L(m)1 + ￿L(m)2 . Lastly, we average these estimates over
m = 1, ...,M to obtain a final estimates ￿L, ￿L1, and ￿L2. The model(s) which yield the largest
cross-validated likelihood values may be considered for the construction of our final working
models. For each selected modeling procedure, we then refit the entire training data set with
the specific modeling procedure in order to construct the final score.
In the BEST trial, 2708 patients were assigned to receive either placebo or bucindolol
(a beta-blocker), with an average followup time of 2 years. In order to select a time point
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representing reasonably long-term outcomes without substantial censoring, we use t0 = 18
months (1.5 years) for the remainder of our analysis, with Gˆj(t0) ≈ 0.80 for each treatment
group. Within the BEST training set, 123, 60, 86, 9, and 84 patients in the control group
were classified as healthy, alive without worsening HF, alive with worsening HF, non-CV
death, and CV death, respectively after 18 months of followup. The corresponding counts
for the treatment group were 148, 74, 52, 13, and 68 patients, respectively. The number of
censored patients were 94 and 89 in control and treatment groups, respectively. We used 16
clinically relevant covariates to fit the patient outcome data with various working models to
estimate the probability of each outcome status at t0 = 18 months. These baseline variables
are: age, sex, left ventricular ejection fraction (LVEF), estimated glomerular filtration rate
adjusted for body surface area (eGFR), systolic blood pressure (SBP), class of heart failure
(Class III vs. Class IV), obesity (Body mass index (BMI) > 30 vs. BMI ≤ 30), resting
heart rate, smoking status (ever vs. never), history of hypertension, history of diabetes,
ischemic heart failure etiology, presence of atrial fibrillation at baseline, and race (white
vs. non-white). As in Castagno et al. (2010), we used 3 indicator variables to discretize
eGFR values into 4 categories, with cut-points of 45, 60, and 75. We used the ordinal
regression models described above to fit the outcome data, and considered both the logit and
complementary log-log links, g(p) = log( p1−p), g(p) = log(−log(1−p)), respectively. For each
of these two models, we used two diﬀerent methods of variable selection. The first one used
all 16 variables additively as well as their interaction terms. The second one used a stepwise
regression procedure. It started from the full model including all 32 covariates (16 × 2) as
well as the treatment indicator τ and successively added/eliminated terms until no more
covariates could be added/removed without subsequently increasing the Akaike information
criterion (AIC). Main eﬀect terms were not eligible to be removed from the model unless
the corresponding interaction term had already been removed. Therefore, a total of four
modeling procedures were considered. To evaluate these models, we used a repeated random
cross validation procedure as described above. In Table 2.3.1, we present these potential
modeling procedures with their corresponding average log-likelihood values. It is interesting
to note that most of these modeling procedures produce similar log-likelihood scores, but
that the models using the complementary log-log link were generally found to produce more
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accurate predictions in each treatment group. The full model using the complementary log-
log link was found to provide the best overall fit in the cross-validation samples and will be
used derive our scores in the following section. As a form of sensitivity analysis, we will also
consider scores derived from the AIC-based model, also using the complementary log-log
link, as this model was found to provide the best fit for the control group patients. We will
refer to these models as the full model and AIC model, respectively.
Table 2.1: Candidate modeling procedures with average cross-validated log-likehoods
Link Function Variable Sel. ￿L1 ￿L
logit Full -108.29 -202.30
logit AIC -107.95 -201.25
cloglog Full -107.56 -201.18∗∗
cloglog AIC -107.52∗∗ -201.29
Table 2.2: Ordinal regression coeﬃcients for the final working models using BEST training
data
Full Model AIC Model
Covariate β β∗ β β∗
Age -0.001 -0.004 - -
Sex: male 0.098 -0.148 - -
LVEF -0.014 -0.019 -0.014 -0.020
I(eGFR>75) -0.175 -0.266 -0.191 -0.278
I(eGFR>60) -0.041 -0.106 - -
I(eGFR>45) -0.656 -0.078 -0.733 -
SBP -0.012 0.008 -0.011 0.007
Class IV Heart Failure 0.191 0.634 0.228 0.601
I(BMI>30) 0.207 0.010 0.197 -
Never-smoker 0.126 -0.128 - -
Heart Rate 0.005 -0.015 0.006 -0.015
History of hypertension 0.213 -0.173 0.147 -
History of diabetes 0.308 -0.233 0.171 -
Ischemic etiology 0.083 0.103 - -
Atrial Fibrillation 0.244 -0.286 - -
Race: white 0.044 -0.198 - -
Treatment - 1.268 - 0.715
β represents main eﬀects in fitted model. β∗ represents
treatment interaction eﬀects.
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2.4 Potential Scoring Systems
Having completed this variable selection and model building step to select the “best” working
models for predicting patient outcomes in both treatment groups, there are two reasonable
ways in which to incorporate covariate information for the purposes of stratifying patients
in the BEST trial. Let treatment group j = 1 denote the untreated (placebo) group, and
j = 2 denote the treated (beta-blocker) group.
2.4.1 Baseline Risk Score
Perhaps the most commonly used method for stratifying patients is by estimated baseline
risk, indexed here by β￿Zij. Denote this score as Rˆ(U). If all modeling assumptions made in
the training data are valid, this linear combination of baseline covariates can be transformed
to give consistent estimates for {π1k(U), k = 0, . . . , 4}, a patient’s true outcome probabilities
if not assigned to treatment. Even if the modeling assumptions are not correct, it is still
plausible to assume that patients with larger risk scores may be generally at higher risk for
more severe clinical outcomes than those with lower risk scores. A recent paper addressing
the appropriate treatment of heart failure patients is indicative of the common clinical focus
on high-risk vs. low-risk patient status, as well as the assumption that absolute treatment
benefits are greatest for high-risk patients (Peterson et al., 2010).
2.4.2 Treatment Selection Score
Another interesting, though perhaps less commonly used, method for stratifying patients is
according to treatment selection score (TSS), which is indexed by β∗￿Zij, the model-based
estimate of the diﬀerential eﬀect of treatment for a patient with given covariates. For a given
U, let this score for the treatment contrast be denoted by Dˆ(U), which intends to estimate
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D(U) = g(γ1k(U))− g(γ2k(U)) for any outcome category k if the modeling assumptions are
true. Since γjk refers to the probability of being in a category equal to, or healthier than,
category k, negative values of D(U) correspond to reduction in overall risk associated with
treatment. If patient i has true values γi1k < γi2k, ∀k, then that patient would unquestionably
benefit from treatment. Conversely, if that patient’s γi1k > γi2k, ∀k, then that patient would
be universally harmed by treatment. While perhaps less intuitive for clinical use, it is clear
that if the modeling assumptions are valid, then this score directly addresses the question
of whether or not a particular patient is a good candidate for treatment. This type of
stratification system has recently been implemented successfully by Cai et al. (2011), who
investigated CD4 changes in HIV patients.
2.5 Making Inferences About the Treatment Diﬀer-
ences over a Range of Scores with Respect to Or-
dered Patient Outcomes in the Target Data Set
Let the final parametric score for a patient with the covariate vector U in the target study
be denoted by S(U), which may be the risk score Rˆ(U), based on the control group only, or
the treatment selection score Dˆ(U) discussed in the previous section.
In order to make inference about the risks and benefits of treatment at the patient level,
we propose to use the same ordered multinomial classification scheme described previously,
in which each patient is classified according to their status at time t0, depending on the par-
ticular set of clinical events which they have experienced. We then construct the confidence
interval and band estimates for the treatment diﬀerences with respect to the probability of
a patient being classified into each possible clinical category.
The target data consist of nj independent and identically distributed observations as
described in the training data. Furthermore, we let {Yijk = I(￿ij = k), k = 0, . . . , 4}, which
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is observable only if min(T(3), t0) ≤ C. For the kth outcome, we are interested in estimating
the treatment diﬀerence conditional on S(U) = s, that is,
Ek(s) = pr(￿i2 = k|S(U) = s)− pr(￿i1 = k|S(U) = s). (2.5)
To estimate Ek(s) nonparametrically, we use a kernel estimator for each term on the right
hand side of Equation (2.5). Specifically, we estimate pjk(s) = pr(￿ij = k|S(U) = s) with
pˆjk(s)
=
￿ nj￿
i
wij
Gˆj(X(3)ij ∧ t0)
Khj(Vij − s)Yijk
￿
/
￿ nj￿
i
wij
Gˆj(X(3)ij ∧ t0)
Khj(Vij − s)
￿
, (2.6)
where Vij = S(Uij), wij = I(X(3)ij ≤ t0)∆(3)ij + I(X(3)ij > t0), Gˆj(·) is the Kaplan-Meier
estimator of Gj(·), the survival distribution of the censoring variable Cj, estimated us-
ing observations {(X(3)ij,∆(3)ij), i = 1, · · · , nj}, Khj(s) = K(s/hj)/hj, K(·) is a smooth
symmetric kernel with finite support and hj is a smoothing parameter. Even though Yijk
may not be observable due to censoring, note that wijYijk is always observable. When
hj = O(n−v), 1/5 < v < 1/2, it follows from a similar argument by Li et al. (2011) that
pˆjk(s) converges to pjk(s) uniformly over the interval s ∈ S, where S is an interval contained
properly in the support of S(U). Let E(s) = {E0(s), ..., E4(s)}￿ = p2(s)− p1(s) and its em-
pirical counterpart Eˆ(s) = {Eˆ0(s), ..., Eˆ4(s)}￿ = pˆ2(s)− pˆ1(s), where Eˆk(s) = pˆ2k(s)− pˆ1k(s),
pj(s) = {pj0(s), · · · , pj4(s)}￿ and pˆj(s) = {pˆj0(s), · · · , pˆj4(s)}￿
It follows from a similar argument by Li et al. (2011) that when hj is of the same order
as above, for a fixed s, the joint distribution
(n1h1 + n2h2)
1/2{Eˆ(s)− E(s)} (2.7)
converges in distribution to a multivariate normal with mean 0 and covariance matrix Σ(s)
as n→∞.
To approximate the distribution in (2.7), we use a perturbation-resampling method,
which is similar to ‘wild bootstrapping’ (Wu, 1986; Mammen, 1993) and has been successfully
implemented in many estimation problems (Lin et al., 1993; Park and Wei, 2003a; Cai et al.,
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2010). Details are provided in the Appendix. To construct a (1−α) simultaneous confidence
band for Ek(s) over the pre-specified interval S, we also use resampling methods, further
described in the Appendix.
As with any nonparametric estimation problem, it is important that we choose ap-
propriate smoothing parameters in order to make inference about E(s). Here, we use an
M-fold cross-validation procedure to choose the smoothing parameter hˆj which maximizes
a weighted cross-validated multinomial log-likelihood, as in Li et al. (2011). Specifically, we
may randomly divide the entire data set into M mutually exclusive, approximately equally
sized subsets. For any fixed values of hj and (j, k), we can estimate pjk(s) using all obser-
vations except for those contained in the same subset as the ith subject, which yields the
estimator pˆ(−i)jk(s). The cross-validated log-likelihood, adjusted for censoring, is￿
Vij∈S
wij
Gˆj(X(3)ij ∧ t0)
{
4￿
k=0
Yijklog(pˆ(−i)jk(Vij))}. (2.8)
Let hˆj be a maximizer of (2.8). As in Li et al. (2011), hˆj is of the order n−1/5. To
ensure the the bias of the estimator is asymptotically negligible and that the above large-
sample approximation is valid, however, we slightly undersmooth the data and let the final
smoothing parameter be h˜j = hˆj × n−ξ where ξ is a small positive number less than 0.3.
In order to aid in the interpretation of patient outcome probabilities, we may additionally
estimate patient-specific cumulative probabilities by repeating the same procedure as above,
but instead using Y˜ijk = I(￿ij ≤ k), γjk(s) = E(Y˜ijk|s), and Γk(s) = γ2k(s) − γ1k(s). It
should be noted that each value Γk(s) allows for the estimation of the treatment contrast
with respect to a diﬀerent composite outcome. For example, Γ0(s) refers to the eﬀect of
treatment on the composite outcome “any hospitalization or death”; Γ1(s) refers to the
eﬀect of treatment on the composite of “CV hospitalization or death”; Γ2(s) corresponds to
the eﬀect of treatment on “any death”, thus representing the initial primary outcome in the
BEST study; Γ3(s) corresponds to the eﬀect of treatment on CV-related death; Γ4(·) ≡ 0 by
definition, as γ2,4(·) = γ1,4(·) ≡ 1. While a positive (negative) value of particular component
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Ek(s) may not always directly indicate whether a treatment is beneficial (harmful) for a
specific patient, particularly when 0 < k < 4, the corresponding Γk(s) will always have this
desired interpretation, with positive values always indicating beneficial treatment eﬀects, as
our classification scheme orders patient outcomes according to increasing severity.
2.5.1 Patient Outcomes in BEST Trial
First, we present for each treatment group, the total number of patients in the target data
set known to be in each outcome category, as well as the estimated cell probabilities after ad-
justing for censoring. These results are shown in Table 2.5.1. We note that, overall, treated
patients are somewhat more likely to be classified into outcome categories 0 and 1 (alive
with no hospitalizations or non-CV hospitalizations only), and less likely to be classified into
categories 2 and 4 (alive with CV-related hospitalization and CV death, respectively). The
cumulative probabilities of a treated patient being classified at or below a certain thresh-
old suggest an estimated population-level beneficial eﬀect of treatment, regardless of the
threshold used.
Table 2.3: BEST target data, 18-month patient outcomes: Observed patient outcomes and
associated multinomial probability estimates, adjusted for censoring.
Control Group Treated Group
Outcome Category N P(￿ = k) P(￿ ≤ k) N P(￿ = k) P(￿ ≤ k)
(censored) 156 - - 159 - -
0 274 0.384 0.384 294 0.405 0.405
1 114 0.160 0.544 150 0.207 0.612
2 165 0.231 0.775 138 0.190 0.802
3 26 0.031 0.806 26 0.031 0.833
4 162 0.194 1.000 143 0.167 1.000
Now, we apply the final scoring systems to the patients in the BEST trial. In Figure
2.5.1 below, we show the two scores Rˆ and Dˆ for each patient in the BEST target data set,
as derived from the full model described previously, with parameters estimated using the
training set data. It is interesting to note that the two sets of scores show no significant
correlation. The horizontal line indicates Dˆ = 0, and we note that 1284 (71%) of the target
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BEST patients fall below this line, indicating an anticipated treatment benefit for a majority
of patients.
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Figure 2.1: Risk Scores (R) and Treatment Selection Scores (D) for target BEST patients
using models derived from BEST training data.
To estimate p1(s), p2(s) and E(s) in our analysis below, we let K(·) be the standard
Epanechnikov kernel. The smoothing parameters were chosen as the maximizers of (2.8),
then multiplied by n−0.05j .
Risk Score:
We may first validate our model-based risk score by observing the relative frequency of pa-
tient outcomes in the BEST placebo group only, as a function of the baseline risk score
Rˆ. In the left panel of Figure 2.5.1 below, the estimated control and treatment group out-
come probabilities (solid and dashed lines, respectively) pˆ(s) are displayed over the range
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s ∈ (−0.70, 1.40). We note that the parametric risk score Rˆ is closely related to the non-
parametrically estimated probabilities pˆ0(s) and pˆ4(s). That is, increasing risk scores are
associated with increased risk of experiencing CV death (￿ = 4), and decreasing risk of re-
maining completely event-free (￿ = 0) in both treatment groups. The other three outcomes
(￿ = 1, 2, 3) show relatively little overall association with the risk score. In the right panel,
we see the estimated cumulative probabilities, representing the probability of a patient being
classified at, or lower than, a given threshold. As expected, we see that, regardless of the
threshold used, a patient’s risk declines with increasing risk scores. In the bottom right
panel, we present the distribution of the risk scores used in this analysis.
In order to determine whether the baseline risk score can be eﬀectively used for patient-
level treatment decisions, we evaluate the estimated treatment eﬀects Eˆ(s) and Γˆ(s) over
the range of scores. In the right panel of Figure 2.5.1, we show the treatment eﬀects,
reflecting the diﬀerence in outcome probabilities (treated minus untreated) for each patient
outcome category. Estimated 95% confidence intervals are denoted by dashed lines, and
95% confidence bands are represented by the shaded areas. In general, we find that lower-
risk patients (e.g. Rˆ < 0), are generally more likely to be classified into outcome category
1 (non-CV hospitalization only), and less likely to be classified into outcome categories 2
(CV hospitalization) and 4 (CV death) as a result of treatment, while high-risk patients
(e.g. Rˆ > 1) are more likely to be classified into outcome category 0 (no clinical events) as
a result of treatment, though the variability of the estimates increases in this range. The
only treatment eﬀects found to be significant with respect to the 95% confidence bands are
associated with lower risk scores, as scores in the range (-0.33, 0.00) are associated with
significant increases in the probability of experiencing the outcome ￿ ≤ 1 (alive without CV
hospitalization) as a result of treatment. The more restrictive range (-0.24, -0.12) is further
associated with significant increases in experiencing the outcome ￿ ≤ 2 (alive) and ￿ ≤ 3
(no CV death) due to treatment. These ranges represent approximately 23% and 8% of the
patients in the BEST population, respectively.
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Figure 2.2: BEST target patient outcomes using baseline risk (Rˆ) as a scoring system.
Solid lines: Placebo Group; Dashed lines: Treatment Group
Left panels: specific outcome probabilities; Right panels: cumulative outcome probabilities
Bottom right: Distribution of scores
Treatment Selection Score:
Using the TSS, we find that Dˆ, a patient’s model-based estimated eﬀect of treatment on
outcome status is related to the nonparametrically estimated treatment eﬀect on a patient’s
probability of experiencing outcome category ￿ = 0 (alive without any hospitalizations) and
￿ = 2 (alive with CV hospitalization), Eˆ0(s) and Eˆ2(s). Specifically, using TSS as our scoring
system over the range s ∈ (−1.08, 0.76), we find Eˆ0(s) > 0 for s < −0.08 and Eˆ0(s) < 0
for s > −0.08, indicating that our treatment interactions estimated from the BEST training
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Figure 2.3: BEST target treatment diﬀerences (treated minus untreated) using baseline risk
(Rˆ) as a scoring system.
Left panels: specific outcome probabilities; Right panels: cumulative outcome probabilities
Bottom right: Distribution of scores
data appear to be helpful in predicting which patients would benefit from being treated with
beta-blockers, though not necessarily with respect to mortality outcomes. In particular,
patients with TSS ∈ (−0.94,−0.30) are found to be significantly more likely (via the 95%
confidence band) to experience outcomes ￿ ≤ 1 (alive with no CV hospitalization), a range
of scores representing approximately 36% of the patients in the target data set. Treatment
eﬀects Eˆ(·) and Γˆ(·) are shown below in Figure 2.5.1. It is interesting to note that the
estimated eﬀect of treatment in terms of reducing the risk of death is relatively constant,
and nonsignificant, with a risk reduction of approximately 2% across the range of scores.
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Thus, it may be fair to declare a particular future patient to be a good or bad candidate for
treatment on the basis on the treatment selection score, which is able to identify patients
who would likely benefit from treatment in terms of avoiding CV-related hospitalization.
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Figure 2.4: BEST target treatment diﬀerences (treated minus untreated) using treatment
selection score (Dˆ) as a scoring system.
Left panels: specific outcome probabilities; Right panels: cumulative outcome probabilities
Bottom right: Distribution of scores
2.5.2 Sensitivity Analysis using AIC model
Because our cross-validation procedure did not suggest that any particular model would fit
the training data substantially better than the other candidate models, we repeat the above
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procedure using the risk score and treatment selection score, as derived from the AIC model.
From this model, there is a slight but significant positive correlation (ρ = 0.17) between the
risk score and the treatment selection scores, suggesting that low-risk patients are generally
expected to benefit more greatly from treatment than high-risk patients. In Figures 2.5.2
and 2.5.2 below, the treatment diﬀerences as a function of each of these scores are shown
along with 95% confidence bands and intervals. The results are generally the same as when
using the scores deriving from the full model. The most notable diﬀerence is that, using
the treatment selection score deriving from the AIC model, in addition to detecting a range
of patients who would be benefit significantly, via the 95% confidence intervals, in terms of
avoiding CV-related hospitalization and/or death (￿ ≤ 1), representing approximately 50%
of the BEST population, a smaller subset of these patients, with TSS ∈ (−0.64,−0.32) are
found to benefit from treatment with respect to overall mortality and/or CV-related death
(￿ ≤ 2, ￿ ≤ 3). This smaller subset of scores is associated with approximately 25% of the
BEST patient population.
2.5.3 Conclusions
Ultimately, despite the non-significant overall result in the BEST trial, both of our scoring
systems are able to identify a sizeable subgroup of BEST patients who would experience
significant benefits from treatment with beta-blockers (i.e. bucindolol), in each case repre-
senting approximately one fourth to one half of the BEST patient population, depending
on whether 95% confidence intervals or bands are being used to determine statistical signif-
icance.
The results from our analysis using the baseline risk score are particularly interesting in
that the observation that low-risk patients may derive equal (or possibly greater) benefits
from treatment than high-risk patients seems to oppose clinicians’ conventional wisdom.
This finding may have implications for design of future studies.
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Figure 2.5: BEST target treatment diﬀerences (treated minus untreated) using baseline risk
(Rˆ) from the AIC model as a scoring system.
Left panels: specific outcome probabilities; Right panels: cumulative outcome probabilities
Bottom right: Distribution of scores
The results from our analysis using the treatment selection score are interesting for
the reason that our scoring system, though not perfectly predictive of all clinical outcomes,
seems to have done a reasonably good job of separating patients who would respond well
to treatment (TSS< 0) from those who would respond poorly (TSS> 0). In this sense, we
have found evidence of treatment interactions that are identifiable early in the course of the
clinical trial and which are prospectively validated using future patients.
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Figure 2.6: BEST target treatment diﬀerences (treated minus untreated) using treatment
selection score (Dˆ) from the AIC model as a scoring system.
Left panels: specific outcome probabilities; Right panels: cumulative outcome probabilities
Bottom right: Distribution of scores
2.6 Remarks
In this analysis, we use a two-stage process that can rather easily be applied in other scenarios
with randomized clinical trial data. Here, we use two independent data sets obtained by
separating the patients in a single clinical trial into two groups according to the order in
which they were enrolled, thus utilizing a training data set similar to that which may be
available at the time of an interim analysis. We utilize these independent data sets to
construct a systematic, subject-specific treatment evaluation procedure. The final scoring
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system may be chosen via a complex, exploratory model and variable selection process using
the training data set. We then apply this system to stratify the patients in the second group
and make inferences about the treatment eﬀects with respect to various patient outcomes
for each stratum. If two similar studies are available, as in many industry settings where
two Phase III trials are required, one may instead treat the data from the first trial as the
training data set and stratify and evaluate patients in the second trial accordingly.
Because our goal is to develop a score to group patients with similar treatment responses,
the treatment selection score Dˆ(·) should be the most eﬀective system with which to stratify
patients. However, there are practical concerns that could result in the preference of scoring
system Rˆ(·) based on the control group only. In particular, if there are multiple treatments
options to be compared, it will not be feasible to build a separate treatment selection scores
for each pairwise treatment comparison, and the baseline risk score would be an intuitive
choice to investigate the eﬀects of each treatment. Additionally if there are two trials of
interest in the same disease setting but the patient populations and/or treatments are not
known to be comparable across trials, then the treatment selection score Dˆ may not generalize
well from one trial to another. For example, trials involving HIV-infected patients continually
evaluate diﬀerent combinations of approved therapies. Moreover, clinical practitioners seem
more comfortable at present with the idea of using a risk score from the control arm to
make treatment decisions; we show, however, in Figure 2.5.1 that the common belief that
the patients with the worst prognosis will benefit the most from treatment may not hold
true.
In this paper, we used the t0-year outcome probabilities as the parameters of interest,
where t0 may be chosen from a clinical perspective. In practice, one may repeat this proce-
dure with various time points. It would be interesting to choose a global measure to quantify
the treatment contrast. Further research is warranted along this line.
Our model and variable selection procedure is intended to select the “best” model for
fitting the data in terms of overall log-likelihood. When the endpoint is the treatment
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diﬀerence, it is not clear that our approach of attempting to find a working model which
best fits the data in this general sense would necessarily produce the “best” treatment
selection score, as interactions between treatment and covariates become more important,
while main eﬀect terms may be thought of as nuisance parameters. In his unpublished thesis,
Signorovitch (2007) proposed a novel method for modeling the treatment contrast directly
with covariates for binomial outcomes. Intuitively, this approach would more eﬀectively
select the treatment and covariate interactions for creating the score. Further research is
needed to evaluate scoring systems with respect to the subject-specific treatment diﬀerences.
Lastly, the choice of treatment based on a risk-benefit perspective is quite individual-
ized. A global summary of the treatment eﬀectiveness, for example, the risk-benefit ratio,
may not provide enough information for personalized medicine. Instead, summaries for the
treatment’s combined toxicity and eﬃcacy at the subject level, as we have proposed in this
article, can be quite useful for the patient’s bedside management.
2.7 Appendix
Construction of Confidence Intervals and Bands
Let {Bij : i = 1, ..., nj; j = 1, 2} be independent random samples from a strictly positive
distribution with mean and variance equal to one. Let p∗jk(s) be the perturbed version of
pˆjk(s) with p∗jk(s)
=
￿￿
i
Bijwij
Gˆ∗j(X(3)ij ∧ t0)
Khj(Vij − s)Yijk
￿
/
￿￿
i
Bijwij
Gˆ∗j(X(3)ij ∧ t0)
Khj(Vij − s)
￿
. (2.9)
Here, Gˆ∗j(·) is the perturbed estimator for the survival function Gj(·)
Gˆ∗j(t) = exp
￿
−
nj￿
i=1
￿ t
0
Bijd{I(Cij ≤ u ∧X(3)ij)}￿nj
l=1BljI(X(3)lj ≥ u)
￿
. (2.10)
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Denote E∗(s) = p∗2(s)− p∗1(s), where p∗j(s) = {p∗j0(s), · · · , p∗j4(s)}￿. Using the arguments by
Cai et al. (2010), the limiting distribution, conditional on the target data set, of
(n1h1 + n2h2)
1/2{E∗(s)− Eˆ(s)}, (2.11)
is multivariate normal with mean 0 and covariance matrix Σ(s).
In order to obtain an approximation toΣ(s), we generate a large number of realizations of
{Bi1, Bi2} from a standard exponential distribution, and compute E∗(s) for each perturbation
sample. The resulting sample covariance matrix based on those perturbed estimates E∗, say,
Σ˜(s), is a consistent estimator of Σ(s). A two-sided confidence interval for an individual
risk diﬀerence Ek(s) is then given by
Eˆk(s)± z(1−α/2)(n1h1 + n2h2)−1/2σ˜k(s), (2.12)
where σ˜k(s) is the kth diagonal element of Σ˜(s).
To construct a (1 − α) simultaneous confidence band for Ek(s) over the pre-specified
interval S, we cannot use the conventional method based on the sup-statistic,
sup
s∈S
σ˜−1k (s)|(n1h1 + n2h2)1/2{Eˆk(s)− Ek(s)}| (2.13)
due to the fact that as a process in s, (n1h1 + n2h2)1/2{Eˆk(s)−Ek(s)} does not converge to
a process. On the other hand, one may utilize the strong approximation argument given in
Bickel and Rosenblatt (1973) to show that an appropriately transformed sup of Eˆk(s)−Ek(s)
converges to a proper random variable. In practice, to construct a confidence band, we can
first find a critical value bα such that
pr(sup
s∈S
|E∗k(s)− Eˆk(s)|/{(n1h1 + n2h2)−1/2σ˜k(s)} > bα) ≈ α. (2.14)
Then the confidence band for Ek(s) : s ∈ S is given by
Eˆk(s)± bα(n1h1 + n2h2)−1/2σ˜k(s). (2.15)
Identical arguments are used for making inference with respect to Γk(s).
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3.1 Introduction
In many randomized studies, multiple events and associated failure times may be recorded
for each patient. For example, in a recent cardiology study, event times corresponding
to hospital admissions, myocardial infarction (MI), heart transplant, and death were all
recorded. In such trials, it may be desirable for the investigators to assess the overall impact
of treatment on patient health, as defined by the absence or occurrence of many events,
while acknowledging a natural ordering to the severity of the events (e.g. hospital admission
in general is less severe than MI, which is less severe than death). In such a situation, each
patient may be evaluated at a fixed time and assigned an ordinal outcome status that acts as
a summary of all clinical events experienced by a patient from randomization until the time
of evaluation. In this paper, we propose methods to analyze such data over time, drawing
connections to existing survival and ordinal regression techniques, allowing one to obtain a
global summary of treatment impact.
Even though multiple patient outcomes are often observed in a study, investigators must
often choose a single primary outcome, with the corresponding between-group comparison
serving as the primary analysis of study, and upon which a decision as to the success of the
treatment may be based. In recent years, seeking to gain eﬃciency, many trials have used
combinations of clinical outcomes as a composite response score (Friedman et al., 2010).
Noted challenges with this approach include the concerns that component outcomes may or
may not have equal clinical importance, and that a single component may “dominate” the
composite outcome (Ferreira-Gonza´lez et al., 2007; Tomlinson and Detsky, 2010). Methods
such as Q-TWiST have been proposed in the context of cancer trials where patients are
observed to transition from one health state to another over time (i.e., toxicity, time without
symptoms and toxicity, relapse), but the procedure may be diﬃcult to interpret when more
than three states are involved, and inference depends on the specification of subjective utility
weights associated with each health state (Gelber et al., 1995, 1996). Many methods have
been proposed, primarily for the purposes of risk-benefit assessment, which classify patients
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according to their overall response at the end of the trial (Chuang-Stein et al., 1991; Boers
et al., 2010). These methods also generally require subjective utility weights and/or may
ignore a patient’s clinical experience over time. Follmann (2002) proposed the usage of
multiple events for each patient in order to describe patients’ overall clinical response, but
did so for the purposes of ranking patients with respect to one another at the end of the
trial. In this paper, we propose methods that estimate an overall summary of the eﬀects of
treatment and/or assess the eﬀect of treatment as a function of time, taking into account
patient health status as it changes over time, without the need to specify utility weights
associated with each health state.
3.1.1 Notation: Progressive Disease State
Suppose we have an integer-valued variable denoting patient health status over time, E(t) ∈
{0, . . . , K}, where larger values generally denote worse health. We focus our attention on the
setting of a progressive disease model, defined by the following properties, and will discuss
later when such assumptions may be relaxed. Suppose E(t) has the following properties:
• a) E(0) = 0;
• b) E(t) ≤ E(s) ∀s > t.
Now, for each patient, define the ‘exit time’ Tk = min{t : E(t) ≥ k},for k ∈ {1, . . . , K}.
Conversely, Ei(t) =
￿K
k=1 I{Tik ≤ t}.
Alternatively, suppose there are K types of “events” which a patient may experience,
ordered by severity where event type K is the worst. For the ith patient {i = 1, . . . , n},
define T ∗ik be the time to first instance of an event associated with severity level k. Let Ci be
the patient’s censoring time, which is assumed to be independent of T ∗ik. The observable data
for each patient is {(Xik,∆ik), k = 1, . . . , K} where Xik = min(Tik, Ci), ∆ik = I(Tik ≤ Ci),
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Tik = min{T ∗ik, . . . , T ∗iK}, and I(·) is the indicator function. We note that the vectors Xk
and Tk will be ordered monotonically (i.e., Xi1 ≤ Xi2 ≤ . . . ≤ XiK , Ti1 ≤ Ti2 ≤ . . . ≤
TiK , i = 1, . . . , n), even though the original event times T ∗k may not be ordered. The “event”
associated with level k may be a singular event, a particular recurrence of an event, or perhaps
a combination of events (e.g. death due to a particular cause). As such, some events may
compete with other events, and an observed finite value of one T ∗k may necessarily result
in a censored value for a competing T ∗j . Let Sk(t) = P (Tk > t) = P (E(t) < k). Let Z
denote treatment assignment (Z = 1, 0 for treated and untreated groups, respectively). The
goal is to estimate the joint eﬀect of treatment on the functions {Sk(t), k = 1, . . . , K}. The
relationship between treatment assignment and time-dependent patient outcome status may
be analyzed via several diﬀerent methods, some requiring stronger parametric assumptions
than others. In this paper, we present three general approaches to this problem, with each
subsequent approach requiring stronger assumptions than the last.
3.2 Integrated General Risk Diﬀerence
The general risk diﬀerence has been studied extensively as an extension of the simple risk
diﬀerence for ordinal data with more than two outcomes (Simonoﬀ et al., 1986; Edwardes
and Baltzan, 2000; Lui, 2002). With two exposure categories, here Z = 0, 1, the general
risk diﬀerence is P (Ei > Ej|Zi = 0, Zj = 1) − P (Ei < Ej|Zi = 0, Zj = 1), with posi-
tive values suggesting that treated patients are generally more likely to be in a “healthier”
state than their untreated counterparts. Evaluated at a fixed time t, this type of mea-
sure is closely related to Somers’ d statistic as well as Wilcoxon’s rank-sum statistic, and
can further be shown to reduce to the simple risk diﬀerence P (E = 1|Z = 0) − P (E =
1|Z = 1) when E is a binary response (Agresti, 1990; Edwardes, 1995). Specifically, de-
fine the general risk diﬀerence with respect to patient outcomes at time t as GRD(t) =￿K
k=1 π0,k(t){
￿k−1
j=0 π1,j(t)}−
￿K
k=1 π1,k(t){
￿k−1
j=0 π0,j(t)}, where π(t)j,k = P (E(t) = k|Z = j).
Let￿GRD(t) =
￿K
k=1 πˆ0,k(t){
￿k−1
j=0 πˆ1,j(t)} −
￿K
k=1 πˆ1,k(t){
￿k−1
j=0 πˆ0,j(t)} where πˆj,k(t) is a
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consistent estimate of πj,k(t).
With complete data, the empirical estimates πˆ(t)j,k =
￿
i I(Ei(t)=k|Z=j)￿
i I(Zi=j)
could be used.
Censoring will in general prevent the observation of {I(Ei(t) = k), t ≥ Ci} for any outcome
level k < K. However, the nature of the progressive disease model implies that I(Ei(t) ≥ k)
may be observable for some levels k. Specifically, I(Ei(t) ≥ k) = 1, {k ≥ Ei(Ci), t ≥ Ci}.
Noting that each group-specific survival curve Sj,k(t) = P (E(t) < k|Z = j), we may define
πˆj,k(t) = Sˆj,k+1(t)− Sˆj,k(t), with Sˆj,0(·) = 0, Sˆj,K+1(·) = 1 for mathematical convenience.
Noting that the integrated diﬀerence in Kaplan-Meier curves is a commonly used model-
free estimate of treatment eﬀect, which is interpreted as “excess restricted mean survival
time due to treatment,” we introduce a generalization to this approach by integrating
the estimate￿GRD(t) over time. Define IGRD(t) =
￿ t
s=0GRD(s)ds, and its estimator
￿IGRD(t) =
￿ t
s=0
￿GRD(s)ds =
￿ t
s=0 Pˆ (Ei(s) > Ej(s)|Zi = 0, Zj = 1)ds −
￿ t
s=0 Pˆ (Ei(s) <
Ej(s)|Zi = 0, Zj = 1)ds. The first component
￿ t
s=0 Pˆ (Ei(s) > Ej(s)|Zi = 0, Zj = 1)ds has
the interpretation of average person-time spent with treated patients in better health than
untreated patients. Conversely,
￿ t
s=0 Pˆ (Ei(s) < Ej(s)|Zi = 0, Zj = 1)ds has the interpre-
tation of average person-time spent in which untreated patients are in better health than
treated patients. Thus the diﬀerence of these two measures can be interpreted as “excess
time spent in improved health due to treatment”.
Alternatively, for any two patients (i, j) at some follow-up time t∗, the duration of
followup may be partitioned into three components, such that t∗ =
￿ t
0 I(Ei(s) < Ej(s))ds+￿ t
0 I(Ei(s) = Ej(s))ds +
￿ t
0 I(Ei(s) > Ej(s))ds = t
∗
i + t
∗
e + t
∗
j , representing the cumulative
time in which patient i is in better, equal, and worse health than patient j, respectively. The
diﬀerence in times t∗i − t∗j represents the excess time spent in improved health for patient i
relative to patient j. The value IGRD(t) can be thought of as the expected value of this
diﬀerence, conditioning on Zi = 1, Zj = 0. This alternative formulation is derived in the
Appendix.
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In order to approximate the variance of ￿IGRD(t) − IGRD(t), we may employ
perturbation-resampling methods to estimate the variance of￿IGRD
∗
(t)−￿IGRD(t), where
￿IGRD
∗
(t) =
￿ t
s=0
￿GRD
∗
(s)ds, (3.1)
￿GRD
∗
(t) =
K￿
k=1
π∗0,k(t){
k￿
j=0
π∗1,j(t)}−
K￿
k=1
π∗1,k(t){
k￿
j=0
π∗0,j(t)},
πˆ∗j,k(t) = Sˆ
∗
j,k+1(t)− Sˆ∗j,k(t),
and Sˆ∗j,k(t) is the perturbed Kaplan-Meier estimator
Sˆ∗j,k(t) = exp
￿
−
￿
i:Zi=j
￿ t
0
Bid{I(Ci ≤ u ∧Xik)}￿
l:Zl=j
BlI(Xik ≥ u)
￿
, (3.2)
where each perturbed value￿IGRD
∗
(t) employs a vector of standard exponential random
variables {Bi, i = 1, . . . , N}, generated independently of the data. This type of procedure
has been applied successfully in previous work such as Park and Wei (2003b), Cai et al.
(2005), and Uno et al. (2007b).
3.3 Repeated Ordinal Regression
Another option for quantifying the impact of treatment at a fixed follow-up time t0 is via
an ordinal regression model (McCullagh, 1980). In the generalization of ordinal logistic
regression models known as the cumulative link model, the typical setup involves a categorical
outcome variable Y with γk = P (Y ≤ k) = g−1(θk +X ￿β) for some general covariate vector
X and a monotonic link function g(·) (Agresti, 1990). In our setup, the outcome is related
to the treatment assignment via the model
g(γk) = θk + Z
￿β, (3.3)
If we let Yi = Ei(t0) for a fixed time t0, then each patient’s log-likelihood contribution
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is given by
Li =
K￿
k=0
πI(Yi=k)ik
=
K￿
k=0
{γik − γi(k−1)}I(Yi=k)
=
K￿
k=0
{g−1(θk + Z ￿iβ)− g−1(θk−1 + Z ￿iβ)}I(Yi=k) (3.4)
With complete data, it is possible to maximize the above likelihood with respect with
respect to {(β, θk), k = 0, . . . , K − 1}, where γiK ≡ 1, γi(−1) ≡ 0 by definition. However, the
independent censoring process will prevent the observation of patient outcomes if the patient
was not in a “terminal state” at the time of censoring, as defined below.
3.3.1 Definition and Notation for Terminal States
It is possible that the definitions of the clinical events used to construct the patient outcome
ranking system may result in a set of “competing” outcomes. For example, if the event “death
due to heart failure (HF)” is associated with patient outcome level K, while “non-HF death”
is associated with outcome level K − 1, then it is clear that T ∗K−1 will censor T ∗K for a given
patient, and vice versa. Thus the observation of T ∗K−1 indicates that a patient is in a terminal
state, and, for such a patient, P [E(t) > (K − 1)] = 0 for any time t. Specifically, we define
a vector V indicating terminal states, where Vk = 1 if P (
￿
j≥k∆ij = 1|∆ik = 1) = 1 and
Vk = 0 otherwise. In the progressive disease model, patients cannot exceed state K, and so
VK = 1. Using this notation, let us further define for each patient TiT = mink{T ∗ik : Vk = 1},
as the time to entering a terminal state, XiT = min(TiT , Ci), and ∆iT = I(TiT ≤ Ci). By
the definition of a terminal state, Ei(s) is known for any s > TiT when ∆iT = 1, and so each
patient’s status at a fixed t0 is determined at (t0 ∧ TiT ).
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3.3.2 Weighted Cumulative Link Model
Using this information, we may modify the log-likelihood from the above cumulative link
model by applying inverse probability of censoring weights and maximizing the standard
weighted multinomial log-likelihood function
￿
i
wi
Gˆ(XiT ∧ t0)
{
K￿
k=0
I(Yi = k)log(πik)}, (3.5)
where πik = g−1(θk+Z ￿iβ)−g−1(θk−1+Z ￿iβ), Gˆ(·) is the Kaplan-Meier estimator of G(·),
the survival function for the censoring variable C, and wi = I(Ci > t0) + I(XiT < Ci)∆iT is
one if a patient’s outcome status is observable at time t0 and zero otherwise. For a specific
followup time t0, we may denote the resulting maximizing value β as βˆ(t0).
In order to assess the treatment eﬀect over time, one may repeat this procedure at
multiple followup times t1 < t2 < . . . < tJ . If we suspect that the true treatment ef-
fect may be constant over time (i.e., β(·) = β), then β may naturally be estimated via
a linear combination
￿
j cjβˆ(tj) with
￿
j cj = 1. As in Wei and Johnson (1985) and
Wei et al. (1989), the linear combination with smallest asymptotic variance is given by
c = (c1, . . . , cJ)￿ = (e￿Ψˆ−1e)−1Ψˆ−1e where e = (1, . . . , 1), and Ψˆ is the estimated covariance
matrix of (βˆ(t1), . . . , βˆ(tJ)). The estimated variance for this linear combination is given by
(e￿Ψˆ−1e)−1. If the treatment eﬀect β(·) is constant in time, then such a linear combination
will provide a consistent estimator for β, regardless of the followup times chosen. Even if the
true value β(·) is not constant over time, this linear combination may still provide a useful
summary measure for the “average eﬀect” of treatment over time, however the expected
value of this estimate will naturally depend on the specific times {tj, j = 1, . . . , J} at which
the model is fit (Wei et al., 1989). The covariance matrix Ψˆ may be estimated via a similar
perturbation-resampling procedure to that described in the previous section. Specifically,
for r = 1, . . . , R, we generate a vector of exponential random variables {Bri }, i = 1, . . . , N .
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Then, for each time tj, let βˆ∗r(tj) be maximizer of
￿
i
Briwi
Gˆ∗(XiT ∧ tj)
{
K￿
k=0
I(Yi(tj) = k)log(πik(tj))}, (3.6)
where Gˆ∗(·) is the perturbed version of the Kaplan-Meier estimator Gˆ(·), as in (3.2). Let
βˆ∗(tj) = {βˆ∗r(tj)}, r = 1, . . . , R. Then, each element Ψˆj,j￿ is estimated by Cov(βˆ∗(tj), βˆ∗(tj￿)).
3.4 Global Model
Rather than repeatedly fitting models at multiple time points, we may instead wish to
build the assumption of a constant treatment eﬀect β directly into our model. Recall the
cumulative link model described in the previous section. We have a categorical outcome
variable Y with γk = P (Y ≤ k), and the outcome is related to covariates via the model
g(γk) = θk + Z
￿β, (3.7)
Letting Y (t) = E(t), we can extend this model across time, writing
g(γk(t)) = θk(t) + Z
￿β(t). (3.8)
If we are willing to make the additional assumption that the association between treat-
ment and outcome status β(t) is constant for all t, then (3.8) reduces to
g(γk(t)) = θk(t) + Z
￿β, (3.9)
which we refer to as our proposed global model.
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3.4.1 Relationship to semi-parametric survival models
Recall that, in general, when there is only a single event time, we may express many semi-
parametric survival models as
g(S(t)) = θ∗(t) + Z ￿β (3.10)
for some decreasing function g(·) (Cheng et al., 1995). In our current framework, we have K
such survival models, corresponding to event times Tk, (k = 1, . . . , K). Assuming the same
link function g(·) for each model, we may write this collection of survival models as
g(Sk(t)) = θ
∗
k(t) + Z
￿βk, (3.11)
where θ∗1(t) ≥ θ∗2(t) ≥ . . . ≥ θ∗K(t) for each fixed t. Finally, we note that
γk(t) = P (E(t) ≤ k) = P (E(t) < k + 1) = Sk+1(t). (3.12)
Now, if we assume that βk = β ∀k, we see that (3.11) reduces to (3.9), with nuisance
parameters θ∗k(t) ≡ θk−1(t).
We note that, with a single binary covariate Z, a fully saturated model for the state
probabilities over time can be written as
g(Sk(t)) = θk(t) + Z
￿βk(t), (3.13)
where the treatment eﬀect βk(t) is allowed to vary with time t and/or outcome status k.
The assumption that βk(t) = βk ∀t results in the set of semi-parametric survival models
(3.11). The assumption that βk(t) = β(t) ∀k results in the longitudinal cumulative link
model (3.8). Our proposed model (3.9) results from the simultaneous assumption of these
two relationships (i.e. βk(t) = β, ∀t, k).
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3.4.2 Estimating treatment eﬀect with a single terminal state via
stratified Cox model
When the vector V = {0, . . . , 0, 1}, (i.e., there is only a single terminal state), the estimation
of the parameter of interest, β is relatively straightforward. Each set of exit times Tk can
be thought of as a separate set of failure times to be modeled via a semi-parametric survival
model, with associated score equation Uk(β). In this case, we simply “stack” the data sets
together, and sum the score equations to obtain the full score U(β) =
￿
k Uk(β).
In the special case that the link function g(·) = log(−log(·)), then we note that (3.10) is
equivalent to the Cox proportional hazards model, resulting in a partial likelihood L(β) =￿K
k=1 Lk(β), where
Lk(β) =
n￿
i=1
￿
exp{Z ￿iβ}￿
l∈Rk(Xki) exp{Z ￿lβ}
￿∆ik
, (3.14)
where Rk(t) = {l : Xik ≥ t}, which is similar to Wei et al. (1989) with the constraint
that all βk = β. We further note that the above likelihood takes the same form as a
stratified Cox model with K strata, where the data corresponding to stratum k is simply
{(Xik,∆ik, Zi), i = 1, . . . , n}. We denote the resulting maximizer of L(β) as βˆ. Specifically,
βˆ is found as the solution to the score equation U(β) =
￿
k Uk(β) = 0, where Uk(β) =￿n
i=1∆ik
￿
Zi −
￿
i Yik(Xik)Ziexp{Z￿iβ}￿
i Yik(Xik)exp{Z￿iβ}
￿
, Yik(t) = I(Xik > t).
Because the vector of event times {Xik} are positively correlated within patients, the
standard variance estimate V˜ (βˆ) from the stratified Cox model will underestimate the true
variance V (βˆ), and would result in an anti-conservative test of H0 : β = 0. In the standard
case, with only one terminal state, the robust variance estimator of Lin and Wei (1989)
may be used. Here, Vˆ (βˆ) = D˜￿D˜, where D˜ = U˜I−1, U˜i =
￿
k u˜ik, and u˜ik is the score
residual corresponding to the kth event time from the ith patient, and I =￿k Ik, where Ik
is the information matrix corresponding to the kth data set, {(Xik,∆ik, Zi), i = 1, . . . , n}.
(Therneau and Grambsch, 2000). We may then assume (βˆ − β) ∼ N(0, Vˆ (βˆ)) and apply
standard techniques for hypothesis testing and the construction of confidence intervals.
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3.4.3 Extensions of the Global Model
Estimating Treatment Eﬀect with Competing Risks
When there exist multiple terminal states (i.e.
￿
k Vk > 1), we must introduce further
notation to properly account for competing risks. For any k :
￿
j<k Vj = 0, the score
equation Uk(β) will remain unchanged. For any k :
￿
j<k Vj > 0 , we must modify Uk(β)
as follows. First, we introduce additional notation. Specifically, let ∆∗k = I(T
∗
k ≤ C) and
Rik =
￿
j<k Vj∆∗ij, which takes the value 1 if patient i is observed to enter into a terminal
state which prevents the entrance into state k.
Using the methods of Fine and Gray (1999) methods for the subdistribution of a com-
peting risk, the new score equation Uk(β) is
n￿
i=1
∆ik
￿
Zi −
￿
iwik(Xik)Y
∗
ik(Xik)Ziexp{Z ￿iβ}￿
iwik(Xik)Y
∗
ik(Xik)exp{Z ￿iβ}
￿
(3.15)
where Y ∗ik(t) = 1− I(Xik < t,Rik = 0), wik(t) = I(t∧Xik ≤ Ci)Gˆ(t∧Tik)/Gˆ(t) and Gˆ(t)
is the Kaplan-Meier estimate of the survival function of the censoring random variable C.
When there are multiple terminal states, it is not clear that robust variance procedures
may be applied. For the purposes of hypothesis testing, a permutation test may be used,
wherein the values Zi may be permuted a large number of times R, resulting in vectors
{Zi}r, (r = 1, . . . , R). For each permuted vector {Zi}r, the model is refit, and the resulting
point estimate denoted βˆ∗r . For a two-sided α-level test of the null hypothesis, we reject when￿R
r=1 |βˆ|≥|βˆ∗r |
R ≤ α. Perturbation-resampling techniques and/or bootstrapping may be used to
estimate a confidence interval for the parameter β.
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Alternative Link Functions
For general link functions g(·), Cheng et al. (1995) show that (3.10) can be re-written as
h(T ) = −Z ￿β + ￿, (3.16)
where ￿ ∼ F (·) = 1 − g(·)−1, and h(t) is an unspecified monotone function increasing in t.
They propose a score function based on the relationship between P (Ti > Tj) and (Zi−Zj)￿β
for all pairs (i, j). The resulting point estimate βˆ is the solution to U(β) = 0, where U(β) is
given in eq. (2.3) in Cheng et al. (1995). This can be extended to current setup by solving
for U(β) =
￿K
k=1 Uk(β), where Uk(β) is the stratum-specific score equation, equivalent to
the score equation of Cheng et al. (1995) when using only {(Xik,∆ik, Zi), i = 1, . . . , n}. It is
still possible to perform hypothesis testing and obtain confidence intervals via permutation
tests and resampling techniques as mentioned above.
3.5 Example
Our data set of interest comes from a recent clinical trial, “Beta-Blocker Evaluation of Sur-
vival Trial” (BEST), which compared a beta-blocker (bucindolol) to placebo in patients with
heart failure, with a primary endpoint of all-cause mortality. In this trial, other monitored
patient outcomes included myocardial infarction (MI), all-cause hospitalization, and heart
transplant (Beta-Blocker Evaluation of Survival Trial Investigators, 2001). Note that in the
BEST trial, the non-fatal event times were not censored by other non-fatal event times. This
trial was conducted in the United States and is of interest because of the observed marginally
significant treatment eﬀect (p=0.10), with an estimated hazard ratio of 0.90 (0.78, 1.02) for
the eﬀect of treatment on mortality. Although the results for the primary endpoint were
not found to be significantly in favor treatment, secondary endpoints generally supported a
beneficial treatment eﬀect. Estimated marginal hazard ratios for all-cause hospitalization,
MI, and heart transplant were 0.92, 0.52, and 0.69, respectively.
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These marginal results for each of these endpoints are summarized in Table 3.1.
Table 3.1: Estimated marginal treatment eﬀects with respect to component outcomes
Outcome Events: Placebo Arm Events: Bucindolol Arm HR p-value
Hospitalization 875 829 0.92 (0.84, 1.01) 0.08
MI 85 46 0.52 (0.36, 0.75) <0.001
Heart Transplant 41 29 0.69 (0.43, 1.10) 0.12
Death 449 411 0.90 (0.78, 1.02) 0.10
It is reasonable to assume that these outcomes can be ordered by severity. Naturally,
death may be considered the worst patient outcome, and any patient no longer living at time
t should be assigned to the worst outcome category, in this case E(t) = 4. Among living
patients, a heart transplant represents major surgery and may be considered an indication
that a patient is nearing death. Thus, any patient alive at time t who has undergone a
heart transplant would be classified as E(t) = 3. Among the remaining the patients, MI
represents a relatively serious concern, and any patient who has experienced at least one
MI prior to time t would be classified as E(t) = 2. Among those patients free of major
cardiovascular complications (i.e., alive with no MI or transplant), we may further distinguish
between those who have been admitted to the hospital for any reason (E(t) = 1), and
those who remain completely event-free (E(t) = 0). The maximum follow-up time in the
study was approximately 50 months with mean follow-up time of 24 months (Beta-Blocker
Evaluation of Survival Trial Investigators, 2001). The censoring rate at t=1, 2, and 3 years
was approximately 10%, 30%, and 65%, respectively. The estimated state probabilities, via
the standard Kaplan-Meier curves, are plotted below in Figure 3.1, and the estimated state
probabilities at followup times of 1, 2, and 3 years are shown in Table 3.2 below. We note
that P (E ≤ k|Z = 1) > P (E ≤ k|Z = 0) for all values of k at all three time points in
the table, suggesting that patients receiving bucindolol are generally more likely to be in a
healthier state than their counterparts at a given time. Furthermore, note that the set of
comparisons between P (E ≤ k|Z = 1) and P (E ≤ k|Z = 0), k = 0, . . . K − 1 represents a
set of nested composite outcomes, evaluating the impact of treatment with respect to a) any
clinical event (k=0), b) any major CV complication or death (k=1), c) heart transplant or
death (k=2), and d) death (k=3).
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Table 3.2: Estimated Patient Outcome Probabilities at 1, 2, and 3 years after treatment
initiation
Placebo Bucindolol Placebo Bucindolol
t = 1 years
P (E ≤ 0) 0.487 0.519 P (E = 0) 0.487 0.519
P (E ≤ 1) 0.831 0.856 P (E = 1) 0.345 0.336
P (E ≤ 2) 0.849 0.862 P (E = 2) 0.018 0.006
P (E ≤ 3) 0.858 0.868 P (E = 3) 0.019 0.006
P (E ≤ 4) 1.000 1.000 P (E = 4) 0.142 0.132
t = 2 years
P (E ≤ 0) 0.312 0.351 P (E = 0) 0.312 0.351
P (E ≤ 1) 0.681 0.720 P (E = 1) 0.369 0.369
P (E ≤ 2) 0.701 0.730 P (E = 2) 0.021 0.010
P (E ≤ 3) 0.720 0.745 P (E = 3) 0.018 0.014
P (E ≤ 4) 1.000 1.000 P (E = 4) 0.280 0.255
t = 3 years
P (E ≤ 0) 0.195 0.237 P (E = 0) 0.195 0.237
P (E ≤ 1) 0.546 0.606 P (E = 1) 0.351 0.369
P (E ≤ 2) 0.575 0.619 P (E = 2) 0.029 0.014
P (E ≤ 3) 0.604 0.635 P (E = 3) 0.029 0.016
P (E ≤ 4) 1.000 1.000 P (E = 4) 0.396 0.365
Using the integrated general risk diﬀerence approach, we find that, after four years of
followup, treated patients experienced a significant improvement in overall health, spending
an expected 59.3 days spent in improved health relative to their untreated counterparts,
with a 95% confidence interval of (10.9, 107.8) days, and corresponding p-value of 0.016.
It should be noted that, by this measure, no significant benefit of treatment is detectable
until nearly 1000 days (approximately 2.75 years) after initiation, and that furthermore,
treatment was associated with significant harm through the first 4 months of follow-up with
no positive estimated eﬀect emerging until approximately 1 year after randomization. The
estimated values and corresponding 95% confidence intervals for IGRD(·) are shown in
Figure 3.2. For comparison, the diﬀerence in 4-year restricted mean survival times (with
standard errors) corresponding to the individual Kaplan-Meier curves are 39.9 days (21.3),
55.7 days (21.1), 41.9 days (21.1), and 31.8 days (21.2), corresponding to S1(·), S2(·), S3(·),
and S4(·), respectively.
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Figure 3.1: Estimated distribution of patient outcome status over the duration of BEST
trial. Darker colors represent worsening health status (e.g. k=0 denoted by light gray; k=4
denoted by black.)
A similar trend is detected via the repeated ordinal regression approach. The model
was fit at followup times of 3, 6, 12, 18, 24, 30, 36, and 48 months. Using the logit link,
g(p) = log( p1−p), a positive value of β(t) indicates an increased probability of a patient being
in a lower (healthier) state as a result of treatment. We again find some evidence of early
harm in the treatment group, with βˆ(t1) = −0.09, implying an estimated odds ratio of
0.91 for relationship between treatment and improved health status, though this estimated
odds ratio is not significantly diﬀerent from the null value 1. Under the assumption of a
constant treatment eﬀect over time, the resulting estimate is βˆ(·) = 0.09 with 95% CI (-
0.033, 0.215), implying a non-significant treatment benefit with corresponding odds ratio
of 1.10 (0.97, 1.24), p=0.15. The estimates and 95% confidence intervals for each β(t) are
shown in Figure 3.3. The horizontal dashed line and gray region represent the estimate and
confidence interval for the (assumed) constant value β(·).
Using the global model with the link g(p) = log(−log(p)), corresponding to the
73
0 500 1000 1500
0
20
40
60
80
10
0
Integrated General Risk Difference
Follow-up Time
E
xp
ec
te
d 
D
ay
s 
of
 Im
pr
ov
ed
 H
ea
lth
Figure 3.2: Estimated improvement in cumulative time spent in improved health, with
pointwise 95% confidence intervals.
Wei-Lin-Weissfeld model, the estimated value βˆ in this trial was -0.115, corresponding
to a global hazard ratio of 0.89 associated with treatment. The robust variance pro-
cedure estimates a standard error of 0.050, with resulting 95% confidence intervals for
β = (−0.214,−0.017), HR = (0.81, 0.98), and associated p-value = 0.02, indicating a signif-
icant global benefit from treatment.
3.6 Discussion
In this paper, we discuss three potential approaches to the analysis of longitudinally assessed
ordinal patient outcomes in clinical trials. Such ordinal outcomes are of particular interest
for several reasons. The longitudinal nature of the data more easily allows for the assess-
ment of changing treatment eﬀects over time. The ordinal nature of the data allows for a
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Figure 3.3: Estimated improvement in cumulative time spent in improved health, with
pointwise 95% confidence intervals.
direct and eﬃcient approach to incorporate many composite clinical outcomes into a single
measure, and will provide more power to detect a significant clinical eﬀect if the treatment
improves patient health with respect to several related outcomes. The simultaneous assess-
ment of multiple clinical outcomes often requires the imposition of utility weights to reflect
the relative importance of each outcome with respect to the others. In many cases, these
weights may be subjective and may diﬀer between individual patients and/or clinicians. It
is presumed that a ranking of such outcomes may be more readily agreed upon than a set of
specific weights. In our example data set, we generally find that treatment with bucindolol is
associated with significant improvement in long-term overall patient health, despite possible
early negative eﬀects during the first 6-12 months of treatment. These message seems to be
consistent, regardless of the methods used.
Each of the three approaches described above, the integrated general risk diﬀerence
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(IGRD), repeated ordinal regression, and the global survival model, has its own strengths
and weaknesses. The IGRD approach, for example, requires no assumptions about the dis-
tribution of outcomes at a given follow-up time, and as such, does not require any particular
link function or any other parametric assumptions. Furthermore, this approach easily al-
lows for the treatment eﬀect to change with time, and also provides an interpretable global
summary measure in the form of expected time spent in improved health due to treatment.
However, this approach does not easily allow for the introduction of covariates, beyond the
binary treatment assignment, into the assessment of the treatment impact. Both the re-
peated ordinal regression and global survival models allow for such covariate eﬀects to be
built directly into their respective models. Unless further restrictions are placed on the
repeated ordinal regression models, however, the estimated covariate eﬀects may not be con-
stant across analysis times. If the introduction of covariates into the model is solely for
the purposes of improving the precision of the estimated treatment, then this will pose no
problem. If one is instead interested in the overall eﬀect of a particular set of covariates on
patient outcomes across time, then the global survival model may be preferred. Additionally,
it should be noted that standard software packages may be used to implement the repeated
ordinal regression models with many commonly used link functions, while the global survival
model is diﬃcult to fit in standard software packages except in the special case mentioned
above with g(·) = log(−log(·)) and a single terminal state. Additionally the global survival
model requires the assumption that the treatment eﬀect is constant over time, and the re-
sulting parameter estimate may be interpreted as in a traditional Cox model, with exp{βˆ}
representing the overall hazard ratio for the instantaneous risk of a patient experiencing any
decline in health.
Finally, it may not always be reasonable to impose a progressive disease model as we have
assumed thus far. For example, patient health may improve over time or the criteria used
to assign patients to outcome states may change over time. The correspondence between
longitudinal cumulative link models and the survival function employed in nonparametric
and semiparametric survival methods requires this progressive assumption, and so the global
survival model will likely be impractical in such an unstructured setting. However the IGRD
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and repeated ordinal regression approach can easily be adapted to such a setting. Further
research is needed to develop methods that do not rely on a such progressive disease model.
3.7 Appendix
Alternate Derivation of IGRD(t)
It can be shown that the additional expected amount of time that patients in the treated
group spend in a healthier state than patients in the untreated group is equivalent to the
value of IGRD(t). Let X(t) and Y (t) be the health statuses of a treated and an untreated
patient, respectively. In addition, for specific patient histories x(·) and y(·), let T (x, y)
denote the duration of time, up to some follow-up time τ , spent with x(t) < y(t). We are
interested in E{T (X, Y )− T (Y,X)}.
E{T (X, Y )− T (Y,X)}
=E
￿ τ
0
￿
I{X(s) < Y (s)}− I{Y (s) < X(s)}
￿
ds
=
￿ τ
0
E
￿
E
￿
I{X(s) < y(s)} | Y (s) = y(s)
￿￿
ds−
￿ τ
0
E
￿
E
￿
I{Y (s) < x(s)} | X(s) = x(s)
￿￿
ds
=
￿ τ
0
E
￿
P
￿
X(s) < y(s) | Y (s) = y(s)
￿￿
ds−
￿ τ
0
E
￿
P
￿
Y (s) < x(s) | X(s) = x(s)
￿￿
ds
=
￿ τ
0
E
￿￿
k
I{Y (s) = k}P{X(s) < k}
￿
ds−
￿ τ
0
E
￿￿
k
I{X(s) = k}P{Y (s) < k}
￿
ds
=
￿ τ
0
￿
k
P{Y (s) = k}S1k(s)ds−
￿ τ
0
￿
k
P{X(s) = k}S0k(s)ds (3.17)
=
￿ τ
0
￿
k
{S0,k+1(s)− S0k(s)}S1k(s)ds−
￿ τ
0
￿
k
{S1,k+1(s)− S1k(s)}S0k(s)ds
=
￿ τ
0
￿
K￿
k=1
π0,k(s){
k−1￿
j=0
π1,j(s)}−
K￿
k=1
π1,k(s){
k−1￿
j=0
π0,j(s)}
￿
ds
=IGRD(τ)
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4.1 Introduction
Meta-analysis is a valuable tool for combining information from independent studies, espe-
cially when no single study is able to address the question at hand. The use of meta-analysis
methods has grown substantially in recent years, with over 2000 papers per year published
in PubMed, as of 2006 (Sutton and Higgins, 2008). Among these approaches, fixed-eﬀects
and random-eﬀects models (particularly the DerSimonian-Laird approach) are two of the
most commonly used models in meta-analysis. In practice, however, it is diﬃcult, if not
impossible, to verify the fundamental assumptions of these two models (i.e., one assumes
homogeneous treatment eﬀects across studies in a fixed-eﬀects model or that the underlying
study parameters are samples from a single (often normal) distribution in a random-eﬀects
model). Our question is: Can we develop a meta-analysis framework without taking a leap
of faith to simply adopt these conventional assumptions? In this article, we develop such a
framework to address this question and also provide a theoretical support and valid inference
for related statistical problems.
Suppose that there are K independent studies whose underlying unknown parameters
are denoted by θ1, . . . , θK . We make the minimal assumption that we only know that they are
fixed unknown values, and any or all of them may or may not be equal to one another. In this
context, similar to some nonparametric development, we may prefer to use, say, the median
or other quantiles of the θi’s as an overall quantification for the K studies. Furthermore,
it may often be the case that either the minimum or maximum of a set of parameters is
of particular interest. Finally, we may wish to construct an empirical function and make
inference for the entire range of potential θi values. These considerations are all associated
with the quantiles or the ‘order statistics’ of {θ1, . . . , θK}. Thus, we define the parameter of
interest under this framework as the qth quantile (or the mth smallest) of the θi’s:
θ(m) = the mth smallest θi, i = 1, . . . , K. (4.1)
We would like to make inference for θ(m). Despite that we have defined the underlying
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study parameters, we refer to this setup as a nonparametric framework in the sense that the
assumptions made about models and/or distributions concerning the study parameters are
minimal.
Without loss of generality, as argued in Xie et al. (2009) and Hall and Miller (2010), we
assume that, from the ith study, we have a
√
ni-consistent estimator of θi, say θˆi, where ni is
the sample size of the ith study. In addition, for simplicity and also following Xie et al. (2009)
and Hall and Miller (2010), we assume further that the sample sizes ni →∞ at the same rate
and θˆi ∼ N(θi, s2i ) with the variance s2i = O(1/ni), although the normality assumption can
be relaxed. Let Θ = {θ1, . . . , θK} and Θˆ = {θˆ1, . . . , θˆK}. Also, let N =
￿K
i=1 ni and, without
loss of generality, write ni = λiN for some positive constant λi’s bounded away from zero,
where
￿K
i=1 λi = 1. Our problem now, given the observed data {(θˆi, si, ni), i = 1, 2, . . . , K},
is how to make inference and construct confidence intervals for θ(m) for any particular m.
This seemingly simple and innocent inference setup turns out to be associated with a
well-known diﬃcult problem. Hall and Miller (2010), who studied “the problem of con-
structing confidence intervals or hypothesis tests for extrema of parameters, for example of
max{θ1, . . . , θK},” stated that this type of problem is one of the “important problems where
standard bootstrap estimators are not consistent, and where alternative approaches . . . also
face significant challenges.” The diﬃcult part is the unknown ‘ties’ and ‘near ties’ cases.
Here, a near tie case is defined as
|θj − θ(m)| = O(N−1/2), (4.2)
which is interpreted as that, based on current sample size nj = λjN , a “near tie” parameter
θj can not be distinguished from the parameter θ(m); See Xie et al. (2009) and Hall and
Miller (2010). In these cases, Hall and Miller (2010) stated that “the limiting distribution
of max1≤j≤K θˆj might not be estimable by any method, be it the bootstrap or another
approach.” The approach recommended by Hall and Miller (2010) for this problem, as well as
a set of more general forms of extreme parameters, was to construct a conservative confidence
interval (test) by introducing a constant cα to enlarge the usual confidence interval and use
80
bootstrap to estimate (tune) the constant cα. Although the approach may be practical, it
is conservative and fails to directly address the diﬃcult problem of making inference on the
extrema and other quantiles of the parameters.
In this paper, based on recent developments on confidence distributions (cf., a review
article by Xie and Singh (2012)), we propose a new resampling method to deal with the
inference problem for the extrema of the parameters and also, more generally, for any order
statistics of the parameters. This new resampling method can be viewed as an extension of
the well-studied and widely-used bootstrap method, but it enjoys a more flexible interpreta-
tion and manipulation. In the proposed method, we avoid the diﬃcult problem of estimating
the limiting distribution of θˆ(m). Rather, we directly construct an asymptotic confidence
distribution for θ(m), which can lead to asymptotically proper inference for any ordered pa-
rameters θ(m). The rest of the paper is arranged as follows. In section 2, we introduce and
review the idea of confidence distributions as frequentist distributional estimators, along with
connections to the related bootstrap estimators. In section 3, we propose a general method
for deriving an asymptotic confidence distribution for a particular θ(m), which depends on
a particular set of weights, and propose three reasonable weighting schemes, including the
standard bootstrap estimator. In section 4, we discuss the properties of a set of weights
which will guarantee appropriate asymptotic coverage, show how to construct weights that
possess these properties, and discuss tuning approaches for finite-sample inference. In sec-
tion 5, we present simulation results showing that our proposed weights provide appropriate
coverage in diverse settings. In section 6, we illustrate our method using data from a recently
published meta-analysis investigating the eﬀect of an antioxidant on nephropathy.
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4.2 CD-based Inference
4.2.1 Introduction to Confidence Distribution
In frequentist inference, we often use a single point of sample statistic (point estimator) or an
sample-dependent interval (confidence interval) to estimate a parameter of interest. A confi-
dence distribution (CD) is quite similar, but uses a sample-dependent distribution function,
instead of a single point (point estimator) or an interval (confidence interval), to estimate
the parameter of interest; cf., Xie and Singh (2012) and references therein. A confidence dis-
tribution has also been loosely referred to as a sample-dependent distribution function that
can represent confidence intervals of all levels for the parameter of interest (see, e.g., Cox
(1958); Efron (1993)). The concept has a long history, especially with its early interpretation
associated with fiducial reasoning (see, e.g., Fisher (1973); Cox (2006)). In recent years, the
confidence distribution concept has attracted a surge of renewed attention, and the recent
developments have been based on a redefinition of the confidence distribution as a purely
frequentist concept, without any fiducial reasoning. One nice aspect of this redefinition is
that the confidence distribution is now a clean and coherent frequentist concept (similar to
a point estimator) and is freed from those restrictive, if not controversial, constraints set
forth by Fisher on fiducial distributions. In an invited review article, Xie and Singh (2012)
provided a comprehensive review of the confidence distribution, including its history and a
modern definition as well as its emerging new developments and its intertangled relation-
ship with fiducial and Bayesian inference. A key aspect of the new developments is that a
confidence distribution is “viewed as an estimator for the parameter of interest, instead of
an inherent distribution of the parameter,” which is diﬀerent from the interpretation of a
fiducial distribution or a Bayesian posterior. These developments on confidence distribution
can be viewed as a part of recent developments of distributional inference in statistics, which
include the concepts of generalized fiducial inference, belief function and objective Bayes. Its
role in frequentist inference is similar to that of a posterior distribution in Bayesian inference.
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A confidence distribution is a function of both the parameter and the random sample. It
must satisfy certain requirements in order to provide appropriate inference for the parameter
of interest. The following definition is formulated in Schweder and Hjort (2002); Singh et al.
(2005). In the definition, Ξ is the parameter space of the unknown parameter of interest θ
and X is the sample space corresponding to data Xn = {X1, . . . , Xn}. Singh et al. (2005)
demonstrated that this version of the confidence distribution definition is consistent with the
classical definition which is compiled from confidence intervals of varying confidence levels
(cf., Efron (1993)), and it is easier to use in many situations.
Definition 2.1. A function H(·) = H(Xn, ·) on X × Ξ → [0, 1] is called a confidence
distribution (CD) for a parameter θ, if it follows two requirements: R1) For each given
Xn ∈ X , Hn(·) is a continuous cumulative distribution function on Θ; R2) At the true
parameter value θ = θ0, H(θ0) ≡ H(Xn, θ0), as a function of the sample Xn, follows the
uniform distribution Unif [0, 1]. Also, the function H(·) is an asymptotic CD (aCD), if the
Unif [0, 1] requirement is true only asymptotically and the continuity requirement on H(·) is
dropped.
Based on the definition, any sample-dependent distribution function on the parameter
space can potentially be used to estimate the parameter, but the Unif [0, 1] requirement in
R2 is imposed to ensure that the statistical inferences (e.g., point estimates, confidence in-
tervals, p-values, etc.) derived from the confidence distribution have the desired frequentist
properties. This practice of two requirements has an analog in point estimation: any single
point (a real value or a statistic) on the parameter space can potentially be used to estimate
a parameter, but we often impose restrictions so that the point estimator will have certain
desired properties, such as unbiasedness, consistency, etc. As defined, the concept of confi-
dence distribution is quite broad. It subsumes and unifies a wide range of examples, from
regular parametric (fiducial distribution) examples to bootstrap distributions, significance
(p-value) functions, normalized likelihood functions, and, in some cases, Bayesian priors and
posteriors.
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A simple example of a confidence distribution that has been broadly used in statistical
practice is a bootstrap distribution. Efron (1998) explicitly stated that a bootstrap distri-
bution is typically a “distribution estimator” and a “confidence distribution” function of
the parameter that it targets. Singh et al. (2005, 2007) showed that a bootstrap distribu-
tion typically satisfies the definition of a confidence distribution or an asymptotic confidence
distribution. In any situation where one can construct a bootstrap distribution, one can
construct a confidence distribution or an asymptotic confidence distribution as well.
Another simple example, which is also used by Fisher (1930, 1973) to illustrate his
fiducial function, is from the normal mean inference problem with sample Xi ∼ N(µ, σ2), i =
1, . . . , n. The basic confidence distributions for µ are Φ(
√
n(µ− X¯)/σ) when σ is known and
Tn−1(
√
n(µ− x¯)/s) when σ is not known, and furthermore Φ(√n(µ−X¯)/s) is an asymptotic
confidence distribution when n → ∞. Here, X¯ and s2 are the sample mean and variance,
respectively, and Tn−1 stands for the cumulative distribution function of the t-distribution
with n− 1 degrees of freedom. In other words, N(X¯,σ2) is a “distribution estimator” of µ,
when σ2 is known. The distribution functions Tn−1(
√
n(µ − x¯)/s) or N(X¯, s2) can be used
to estimate µ, when σ2 is not known. Similarly, in the context under consideration in this
article, we can verify from Definition 2.1 that
Hi(t) = Φ
￿
t− θˆi
si
￿
(4.3)
satisfies the requirements of being an asymptotic confidence distribution, thus we can use a
distribution estimator N(θˆi, s2i ) to estimate θi, for i = 1, 2, . . . , K.
Since, for each given sample Xn, a confidence distribution Hn(·) is a cumulative distri-
bution function on the parameter space, we can construct a random variable ξ defined on
X ×Ξ such that, conditional on the sample data, ξ has the distribution H. For example, let
U be a Unif [0, 1] random variable independent of Xn, then ξ = H−1n (U) ∼ H(·), given Xn.
We call this random variable ξ a CD random variable (see, e.g., Singh et al. (2007); Xie and
Singh (2012)).
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Definition 2.2. We call ξ = ξH a CD random variable associated with a confidence distri-
bution H, if the conditional distribution of ξ given the data Xn is H.
A CD random variable has a close association with a bootstrap estimator. In our example
(4.3), a CD random variable ξi follows ξi|x¯ ∼ N(θˆi, s2i ) and we have, asymptotically,
ξi − θˆi
si
￿￿￿￿ θˆi ∼ θˆi − θisi
￿￿￿￿ θ (both ∼ N(0, 1)). (4.4)
This statement is exactly the same as the key justification for bootstrap, with ξi in place of
the bootstrap sample mean θˆ∗i . Thus, a CD random variable ξ can essentially be viewed as
a model-based bootstrap estimator of θi. Indeed, Xie and Singh (2012) demonstrated under
a very general setting that a CD random variable ξ is in essence the same as a bootstrap
estimator or a simple linear transformation of a bootstrap estimator. This close connection
between the CD random variable and a bootstrap estimator may inspire a possible view of
treating the concept of confidence distribution as an extension of a bootstrap distribution,
albeit the concept of confidence distribution is much broader. The connection and the well-
developed theory of bootstrap distributions can help us to understand inference procedures
involving confidence distributions and develop new methodologies. In this article, we utilize
the CD random variable and develop a new simulation mechanism to broaden the applications
of the standard bootstrap procedures. Since a CD random variable is not limited solely to
use as a bootstrap estimator, this freedom allows us to utilize ξ more liberally, which in turn
allows us to develop more flexible statistical approaches and inference procedures.
4.3 Proposed Methodology
As illustrated in (4.3), from the ith study we have a confidence distribution (CD) function
Hi(t) = Φ((t− θˆi)/si) that can be used to estimate θi, for i = 1, . . . , K. Denote by ξi the CD
random variable corresponding to Hi(t) = Φ((t− θˆi)/si), i.e.,
ξi|θˆi, s2i ∼ N(θˆi, s2i ), for i = 1, . . . , K. (4.5)
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Given a particular realized set of {ξi, i = 1, . . . , K} from each of the K studies, we consider
the construction of a weighted average of ξi’s:
ξ∗ =
K￿
i=1
wi,(m)ξi
￿ K￿
i=1
wi,(m). (4.6)
We propose to make inference on θ(m) based on ξ∗. In particular, we can easily simulate
{ξi, i = 1, . . . , K} according to (4.5) and compute ξ∗ according to (4.6). If we repeat this a
large number of times, we can obtain a set of ξ∗’s, which represents a CD for the parameter
θ(m). Then, we can report the mean/median/mode of the ξ∗’s as a point estimate of θ(m),
and the empirical (α/2)100% and (1−α/2)100% quantiles of the ξ∗’s as the level (1−α)100%
confidence interval for θ(m).
The proposed procedure is very simple. Naturally, diﬀerent choices of the weights wi,(m)
lead to diﬀerent procedures, and each procedure’s resulting validity depends on the choice
of its weights. In particular, we consider in this paper the following potential choices of
weights:
Choice 1:
w[1]i,(m) = 1{θˆi = θˆ(m)}, (4.7)
where 1{·} is an indicator function and θˆ(m) is the mth smallest θˆi.
Choice 2:
w[2]i,(m) = 1{ξi = ξ(m)}, (4.8)
where ξ(m) is the mth smallest ξi.
Choice 3:
w[3]i,(m) = K
￿
ξi − ξ(m), bL, bR
￿
(4.9)
where K is a kernel function, and bL, bR represent the left-side and right-side kernel band-
widths. Without loss of generality, we henceforth assume a rectangular kernel, such that
K￿ξi − ξ(m), bL, bR￿ = 1{−bL ≤ (ξi − ξ(m)) ≤ bR}. (4.10)
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Written this way, it is easy to see that w[2]i,(m) represents a special case of w
[3]
i,(m) in which
bL = bR ≡ 0.
Weights w[1]i,(m) and w
[2]
i,(m) both represent intuitively appealing ways of estimating and
making inference on θ(m). The use of w[1]i,(m) is equivalent to using the CD (and resulting
confidence interval) associated with the mth ordered θˆ. The use of w[2]i,(m) corresponds to the
use of the distribution of the mth ordered ξi, and is therefore equivalent to the conventional
bootstrap estimator of θ(m), as discussed in Hall and Miller (2010). Despite these intuitively
attractive qualities, we will show that both sets of weights may lead to undesirable prop-
erties, depending on the true nature of the data, while our third option is flexible enough
to appropriately handle a variety of scenarios while maintaining appropriate coverage levels,
and in many cases, oﬀering narrower confidence intervals than those obtained by the other
weighting schemes. In the following section, we show that there is a very simple requirement
for any given weighting scheme that allows for the use of ξ∗ for asymptotically valid inference
for θ(m). Namely, wi,(m) must converge to a positive constant if θi belongs to the tie or near
tie set of θ(m), as defined below, and zero otherwise. We will show that this requirement is
not satisfied by w[1]i,(m) or w
[2]
i,(m), but is satisfied by w
[3]
i,(m) when (bL, bR) = O(N
−δ), δ ∈ (0, 12).
4.4 Theoretical results
First, let us formally define the tie and near tie sets. The same definition has also been
utilized in Xie et al. (2009); Hall and Miller (2010). In particular, we denote by
Θ(m)T = {j : θj = θ(m), j = 1, . . . , K} (4.11)
the “tie set” of θ(m), representing the set of all θ’s which are equal to the parameter of
interest. We also denote by
Θ(m)N = {j : |θj − θ(m)| = O(N−1/2), j = 1, . . . , K} (4.12)
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the “near tie” of θ(m). The interpretation of the “near tie” definition is that, based on
current sample size ni, a “near tie” parameter θi cannot be distinguished from the target
parameter θ(m). An equivalent expression is that, for any j ∈ Θ(m)N , (θˆj− θˆ(m))−(θj−θ(m)) ￿=
op(|θj−θ(m)|), which means that the diﬀerence between θj and θ(m) is not of greater order than
the standard error of its estimator. Throughout the paper, we assume that both Θ(m)T and
Θ(m)N are completely unknown other than that they contain at least one member θ
(m). Thus,
without loss of generality, we can assume the number of studies in the tie set |Θ(m)T | ≥ 1.
The “near tie” case is much broader than the tie case: Θ(m)T ⊆ Θ(m)N . So, we also have the
number of studies in the near tie set |Θ(m)N | ≥ |Θ(m)T | ≥ 1.
We present next a set of theoretical results using the more general near tie setup. All
results remain valid if Θ(m)N is replaced by Θ
(m)
T .
4.4.1 Asymptotic theorem and properties of proposed weighing
schemes
The following set of asymptotic results suggest that ξ∗ may be used to make inference for
θ(m), if weights are chosen carefully. In the theorem, Ξ is the parameter space of θ(m).
Theorem 4.1. Suppose that we can prove that a set of weights possesses the following
property.
lim
n→∞
wi,(m) =
￿
ci if i ∈ Θ(m)N ,
0 if i ￿∈ Θ(m)N ,
for i = 1, 2, . . . , K (4.13)
for some constants ci > 0. Then, as N →∞, we have the following:
(i)
K￿
i=1
wi,(m)θˆi
￿ K￿
i=1
wi,(m) = θ
(m) + op(1) and
K￿
i=1
w2i,(m)s
2
i
￿￿ K￿
i=1
wi,(m)
￿2
= {s(m)}2 + op(1),
(4.14)
where {s(m)}2 =￿
i∈Θ(m)N
c2i s
2
i
￿￿￿
i∈Θ(m)N
ci
￿2
. Furthermore,
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ξ∗ −￿Ki=1wi,(m)θˆi/￿Ki=1wi,(m)￿￿K
i=1w
2
i,(m)s
2
i /{
￿K
i=1wi,(m)}2
￿￿￿￿Θˆ ∼ ￿Ki=1wi,(m)θˆi/￿Ki=1wi,(m) − θ(m)￿￿K
i=1w
2
i,(m)s
2
i /{
￿K
i=1wi,(m)}2
￿￿￿￿Θ, (4.15)
both converging asymptotically to a N(0, 1) distribution.
(ii) Denote by
H∗(t) = P (ξ∗ ≤ t|Θˆ), for any t ∈ Ξ. (4.16)
When t = θ(m), we have H∗(θ(m)) → Unif [0, 1], in distribution, and therefore H∗(θ) is an
aCD for θ(m).
A proof of the theorem is provided in Appendix.
The function H∗(t) is a cumulative distribution function on the parameter space Ξ and
it also depends on the sample observations Θˆ. Definition 2.1 suggests that, when our weight
choice satisfies the requirement (4.13), H∗(θ) = Pr(ξ∗ ≤ θ|Θˆ) is an aCD for θ(m). Based on
the development on CDs (see, e.g., Singh et al. (2007); Xie and Singh (2012)), it subsequently
ensures asymptotically valid inference, including point estimation, confidence intervals, p-
values, etc., regarding θ(m). Thus, in this case, we can rely on ξ∗ to provide valid inference
for θ(m) asymptotically.
The remaining question is whether any of the three sets of weight choices in Section 3
satisfy the requirement (4.13) and, if they do, under which conditions. Since the asymptotic
properties of each of the proposed weighted estimators depend on the true unknown values
of Θ, we start with the simplest setting of no ties and move on to the more complicated
settings of ties and near ties, including the particularly diﬃcult case in which the presence
of such ties or near ties to θ(m) cannot easily be determined.
The ‘no tie’ case is the case in which |Θ(m)N | = |Θ(m)T | = 1. In particular, this refers to
the case that Θ(m)N and Θ
(m)
T have only one element, and the rest of θj, j ￿∈ Θ(m)N , satisfy the
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condition that
dmN
1/2 →∞, where dm = min
j ￿∈Θ(m)N
￿￿￿￿θj − θ(m)￿￿￿￿ (4.17)
is the minimal distance between the θj’s in and outside the near tie set Θ
(m)
N . The
condition (4.17) is in fact weaker than and covers the conventional assumption of no
ties, in which θ1, θ2, . . . , θK are unknown but distinct constant parameters. In this case,
dm = minθj ￿=θ(m) |θj − θ(m)| ≥ co = mini ￿=j |θi− θj| which is a positive constant bounded away
from zero. There may or may not be ties among the remaining θj’s, but this is irrelevant to
the problem at hand in making inference for θ(m).
Lemma 1 below states that, under the above no tie condition, all the three choices of
weights listed in Section 3 satisfy the condition in (4.13). A proof is given in the Appendix.
Lemma 4.1 (Any Weight; No tie case). Suppose that |Θ(m)N | = |Θ(m)T | = 1 and also
Condition (4.17) holds. For s = 1, 2, we have
lim
N→∞
w[s]i,(m) =
￿
1 if θi = θ(m),
0 if θi ￿= θ(m),
for i = 1, 2, . . . , K. (4.18)
Furthermore, if we use w[3]i,(m) with bL, bR ∝ τN , where τN/dm → 0, and τN
√
N → ∞, then
(4.18) also holds for w[3]i,(m).
Accompanying Theorem 4.1, we can infer from the lemma that in the no tie case, we
can implement the proposed approach using any of the three weight to make asymptotically
valid inference for θ(m). In fact, since (4.18) holds for all s = 1, 2, 3, it is easy to verify,
following the proof of Theorem 4.1, that the inference based on these three diﬀerent choices
of weights are asymptotically equivalent.
The problem in the tie or the near tie case is more complicated. In this case, the
weights w[1]i,(m) or w
[2]
i,(m) for i ∈ Θ(m)T or Θ(m)N converge to random quantities, rather than some
constants ci. We provide below a very simple example in a special case to illustrate the
phenomenon.
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Example 4.1 (Counterexample for w[1]i,(m) or w
[2]
i,(m) in a simple tie case).
Without loss of generality, consider a very simple example of a special case with K = 2 and
θ1 ≡ θ2. For m = 1, Θ(m)T = Θ(m)N = {1, 2} but w[1]1,(m) = 1−w[1]2,(m) = 1{θˆ1 = min(θˆ1, θˆ2)} is a
binary random variable that equals 1 with probability P{θˆ1 ≤ θˆ2} = 1− P{θˆ2 ≤ θˆ1} = 0.5.
Thus, both w[1]1,(m) and w
[1]
2,(m) are (dependent) Bernoulli random variables, each with p = 0.5,
therefore violating (4.13).
Similarly, for m = 1, w[2]1,(m) = 1 − w[2]2,(m) = 1{ξ1 = min(ξ1, ξ2)} is a binary random
variable that equals 1 with probability P{ξ1 ≤ ξ2} = E
￿
P{ξ1 ≤ ξ2|Θˆ}
￿
= E
￿
Φ({θˆ2 −
θˆ1}
￿{s21 + s22}1/2)] = 0.5. Again, both w[2]1,(m) and w[2]2,(m) are (dependent) Bernoulli random
variables, each with p = 0.5, also violating (4.13).
In the case of more than two ties with either |Θ(m)T | > 2 or |Θ(m)N | > 2, the weights w[1]i,(m)
or w[2]i,(m) for i ∈ Θ(m)T or Θ(m)N still converge to random quantities, rather than constants. The
patterns are similar to, but more complicated than, that discussed in the case of |Θ(m)T | = 2
in Example 4.1. Clearly, neither w[1]i,(m) nor w
[2]
i,(m) satisfies the requirement (4.13) in this case,
thus we can no longer ensure that the results from Theorem 4.1 are valid. Our simulation
results confirm that these two sets of weights perform poorly in situations with ties or near
ties. Poor performance of the standard bootstrap procedure, which corresponds to the use
of the second sets of weights w[2]i,(m), was also reported by Hall and Miller (2010).
In contrast, if we use w[3]i,(m) with bL, bR ∝ τN , where τN/dm → 0 and τN
√
N → ∞,
then we can show that (4.13) is satisfied, provided that Condition (4.17) holds. In fact, the
requirement (4.13) is satisfied by w[3]i,(m) in any case, regardless of whether or not any ties
or near ties exist, and regardless of whether or not their existence can be determined from
the data . We summarize the result in the following lemma, together with the result for a
slightly modified w[3]i,(m) choice: ￿w[3]i,(m) = w[3]i,(m)￿si. (4.19)
A proof can be found in the Appendix.
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Lemma 4.2 (Weight w[3]i,(m); Any case). Suppose that Condition (4.17) holds and we use
w[3]i,(m) with bL, bR ∝ τN , where τN/dm → 0, and τN
√
N →∞. For any 1 ≤ |Θ(m)T | ≤ |Θ(m)N | ≤
K, we have
lim
N→∞
w[3]i,(m) =
￿
1 if i ∈ Θ(m)N ,
0 if i ￿∈ Θ(m)N ,
and lim
N→∞
￿w[3]i,(m) =
￿
1/si if i ∈ Θ(m)N ,
0 if i ￿∈ Θ(m)N ,
(4.20)
for i = 1, 2, . . . , K.
This lemma, together with Theorem 4.1, provides a theoretical support to use the
weighted sum of CD random variables ξ∗ to make inference for θ(m) in all cases, if either w[3]i,(m)
or ￿w[3]i,(m) is used. From (4.20), only studies inside the tie and near tie set will be included for
making inference and the studies outside the tie set are filtered out, asymptotically. Thus,
making inference using the proposed method with w[3]i,(m) is asymptotically equivalent to us-
ing the average of the θˆi in the tie set (if we were to know the true tie set). When si’s or
λi = ni/N ’s are heteroscedastic, the modified version ￿w[3]i,(m) could be used to improve the
eﬃciency and power of the inference. In any case, as long as there is a separation between
the studies not tied with θ(m) and those tied with θ(m) as quantified in Condition (4.17), our
proposal provides a class of approaches that can lead us to asymptotically correct inference.
Further details will be discussed in Section 4.2 on the tuning of the kernel widths. Note
that, Condition (4.17) is much weaker than those assumptions imposed in the conventional
fixed-eﬀects and random eﬀects models.
4.4.2 Tuning the bandwidth parameters
Let us first define the bandwidth parameters bL = τN · cL, bR = τN · cR, where τN = O(N−δ)
and cL, cR = O(1). Throughout, we will use τN = (σ)(s(m)/σ)1/2, where s(m) is the standard
error associated with θˆ(m) and σ is reasonable maximum value for the tuning parameter,
such as σ =
￿￿
i s
2
i ∗ni
K . This particular formulation of σ ensures that s
(m)/σ ≈ n−1/2(m) , and
that (s(m)/σ)1/2 > (s(m)/σ). Note that σ = O(1), s(m) = O(N−1/2), and so δ = 1/4.
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While we can guarantee that w[3]i,(m) will provide appropriate asymptotic inference re-
gardless of the selection of tuning parameters (cL, cR), it is important in practice to be able
to select an appropriate value for the tuning parameters (cL, cR) to ensure good finite sample
performance. We note that for suﬃciently large values of (cL, cR), our inference will mimic
a fixed-eﬀects analysis, which is only reasonable under the assumption that |Θ(m)T | = K. On
the other hand, when these bandwidth values are equal to 0, our weights are identical to
w[2]i,(m), which we have shown to be asymptotically valid only when |Θ(m)T | = 1. Thus the
tuning bandwidth values should be relatively large when ties are present and relatively small
when no ties are present. Generally, we refer to θˆj : {θˆj < θˆ(m), θj = θ(m)} as “left side ties”
and θˆj : {θˆj > θˆ(m), θj = θ(m)} as “right side ties”. To this end, we attempt to detect the
presence or absence of left side ties and/or right side ties by observing the behavior of the
realized values of the CD random variables ξ.
In general, we will simulate some large number, R, of samples of our CD random variables
{ξ}, and we may denote the rth sampled value corresponding to θˆ(i) as ξi,r, the rth collection
of sampled values as {ξr} = {ξi,r, i = 1, . . . , K}, and ξ(m)r as the mth smallest value of the
sampled vector {ξr}.
We then define the following terms for the purposes of determining the presence or
absence of tied θ values.
Let πˆi =
￿R
r=1 1{ξ(m)r =ξi,r}
R , and Rˆi = 1{πˆi > 0.001}. Then Tˆ =
￿
i Rˆi, TˆL =
￿
i<m Rˆi,
TˆR =
￿
i>m Rˆi, πˆL =
￿
i<m πˆi, and πˆR =
￿
i>m πˆi. Noting that
￿
i πˆ = 1, and that
Tˆ = (TˆL = TˆR + 1) gives an estimate of the maximum size of the tie set |Θ(m)T |, both πˆL and
TˆL/Tˆ are values between 0 and 1 which provide information about the presence of ties on
the left side of θˆ(m). The geometric mean of these two values c∗L =
￿
πˆL · TˆL/Tˆ then provides
a reasonable summary of the evidence regarding the existence and influence of left side ties,
and similarly c∗R =
￿
πˆR · TˆR/Tˆ on the right.
Empirically, in small sample settings where it is quite diﬃcult to determine whether or
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not there are ties, we find that (c∗R, c
∗
L) may under-smooth the data when |Θ(m)T | is quite large
relative to K, and conversely, may over-smooth the data when |Θ(m)T | = 1. In order to reflect
the true uncertainty as to the size of the tie set, we propose to induce additional randomness
into the smoothing procedure by utilizing cR = u · c∗R, cL = u · c∗L, where u ∼ Unif( 17TˆK , 7TˆK ).
Because 1 ≤ Tˆ ≤ K, we see that 17K2 ≤ u ≤ 7, and therefore, 17K2 ≤ cL ≤ 7, 17K2 ≤ cR ≤ 7
and so u does not influence the convergence rate of the bandwidth parameters bR, bL, and
only serves to induce additional variability into the resulting weighted averages ξ∗.
Thus the algorithm for obtaining the CD used to estimate θ(m) is as follows:
1. Calculate τN using observed (θˆ, sˆ2, n) data.
2. Generate {ξi,r, r = 1, . . . , R} for each study from N(θˆ(i), sˆ2(i))
3. For each vector {ξr}, determine which study i is associated with ξ(m)r .
4. Use these counts to calculate πˆi for each study, and functions thereof (Rˆi,
Tˆ , TˆL, TˆR, πˆL, πˆR, c∗L, c
∗
R).
5. For each r in 1, . . . , R
(a) Generate ur from Unif(
1
7TˆK
, 7TˆK )
(b) ξ∗r =
￿
i ξi,r1{−urτN c∗L≤(ξi,r−ξ(m)r )≤urτN c∗R}￿
i 1{−urτN c∗L≤(ξi,r−ξ(m)r )≤urτN c∗R}
6. The CD for θ(m) is approximated by the empirical distribution Hˆξ∗(θ), and a (1 −
α)100% confidence interval can be estimated by (ξ∗R(α/2), ξ
∗
R(1−α/2)).
4.5 Simulations
In order to demonstrate both small and large sample properties of our proposed esti-
mator under diﬀerent scenarios, we generate random data Xij ∼ N(θi, 1), with θi, i ∈
{1, 2, . . . , K}, 1 ≤ j ≤ ni, taking diﬀerent values according to the particular scenario:
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1. Ties: θi = 0 ∀i
2. Uniform: θi =
i
K+1
3. Normal: θi = Φ−1( iK+1)
For each scenario, we consider K = 7 or K = 21, and we let the sample size from each
study ni = 40, 400, or 4000. Using 500 simulated data sets for each setting, we show the
coverage and median width of the nominal 95% confidence interval.
We consider each of the three methods proposed in Section 2. The results are shown
below. Because each set of {Θ} is symmetric, we need not show results for each ordered θi.
In particular, the coverage and median interval width for any θ(k) will be identical to that
for θ(K+1−k).
For our proposed method using kernel smoothing, the results shown use the tuning
procedure described in the previous section with R=1000 random samples drawn from each
study’s confidence distribution. Simulation results are shown below.
We first note that Method 1 will always return confidence intervals of equal or greater
width than those returned by Method 2. Correspondingly, we find many settings in which the
coverage of Method 2 is far below the nominal level (e.g. the Ties setting, the Uniform setting
with ni = 40). In almost all of these settings (except for m = 1, 2 in the Ties case), Method
1 will provide appropriate, but conservative, confidence intervals. Our proposed Method
3, on the other hand, is shown to have appropriate coverage levels in all settings, as well
as noticeably narrower confidence interval widths relative to Method 1 in nearly all cases.
Relative to the bootstrap estimator (Method 2), the intervals from our proposed method
are narrower, in the fixed-eﬀects setting, for the few cases in which the bootstrap estimator
provides appropriate coverage, and the interval widths are similar (and asymptotically equal)
to those from Method 2 in the uniform and normal settings.
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4.6 Example
To illustrate our proposed methodology, we use the data from 14 studies which assessed
the eﬀect of an anti-oxidant (acetylcysteine) in preventing contrast-induced nephropathy,
a leading cause of acquired acute reduction in kidney function (Bagshaw and Ghali, 2004).
The outcome of interest in each study was incidence of contrast-induced nephropathy, and so
the parameter of interest was the odds ratio for the association between anti-oxidant usage
and incidence of nephropathy. The summary data for each study is shown below.
Table 4.3: Summary results of 14 studies of acetylcysteine for prevention of contrast-induced
nephropathy
Study N OR CI
Allaqaband 85 1.23 (0.39, 3.89)
Baker 80 0.20 (0.04, 1.00)
Briguori 183 0.57 (0.20, 1.63)
Diaz-Sandova 54 0.11 (0.02, 0.54)
Durham 79 1.27 (0.45, 3.57)
Efrati 49 0.19 (0.01, 4.21)
Fung 91 1.37 (0.43, 4.32)
Goldenberg 80 1.30 (0.27, 6.21)
Kay 200 0.29 (0.09, 0.94)
Kefer 104 0.63 (0.10, 3.92)
MacNeill 43 0.11 (0.01, 0.97)
Oldemeyer 96 1.30 (0.28, 6.16)
Shyu 121 0.11 (0.02, 0.49)
Vallero 100 1.14 (0.27, 4.83)
A fixed eﬀects analysis of this data results in a 95% confidence interval of (0.41, 0.87)
for the (assumed) common odds ratio. However, significant heterogeneity was found in the
study-level treatment eﬀects (p=0.032). A random eﬀects analysis, assuming that the logs of
the study-level odds ratios are normally distributed, results in a somewhat wider confidence
interval (0.32, 0.91). Below we show the resulting 95% confidence intervals for each of the 14
ordered study-level treatment eﬀects. The three columns of confidence intervals correspond
to the weighting methods discussed in this article, with the third column representing our
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proposed procedure, which we have shown in simulations to have appropriate coverage,
regardless of whether any or all of the true treatment eﬀects are equal across studies. Even
though we have some evidence to reject the fixed eﬀects assumption, in this example it is
particularly diﬃcult, due to small sample sizes, to assess with any certainty whether or not
any subsets of the study parameters are equal to one another, or whether the assumption
of normal distribution for the log-odds-ratios is appropriate. We note that, in general, the
intervals provided by Method 1 are essentially a re-ordering of the original study intervals,
and thus do not provide substantially new information in terms of summarizing the treatment
eﬀects. The bootstrap intervals corresponding to Method 2, are noticeably narrower in some
cases; however, it is concerning that the interval for θ(14), (1.44, 9.56), excludes even the
maximum estimated treatment eﬀect (estimated odds ratio = 1.37 from the Fung study).
Using our proposed weights (Method 3), we estimate that six of the fourteen studies exhibited
significant treatment eﬀects, while the remaining eight studies were found to be neutral.
The confidence intervals for the 7th and 8th ordered treatment eﬀects are (0.28, 1.01) and
(0.30, 1.07), respectively. Using the conventional method of averaging the (K/2)th and
(K/2+1)th ordered observations to estimate the median when K is an even number, we obtain
a confidence interval of (0.29, 1.04) for the “median” treatment eﬀect across these studies.
This interval is wider than the previously reported random eﬀects analysis, though our
inference is free of any distributional assumptions regarding the true values of the study-level
treatment eﬀects. Furthermore, if the true distribution of the parameters is not symmetric on
the log scale, then our estimate of the median treatment eﬀect will not necessarily be directly
comparable to the random eﬀects analysis, which estimates the mean of the random-eﬀects
distribution.
In Figure 1, we present the 95% confidence intervals for each ordered element of {Θ},
with point estimates given by the mean of the associated confidence distribution. For com-
parison, the confidence intervals for the fixed-eﬀects and random-eﬀects meta-analysis are
denoted by the vertical solid and dashed lines, respectively. Our estimates for θ(7) and θ(8)
are highlighted for comparison.
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Table 4.4: 95% Confidence Intervals for ordered study-level treatment eﬀects using nephropa-
thy data
OS CI (Method 1) CI (Method 2) CI (Method 3)
1 (0.02, 0.48) (0.01, 0.13) (0.01, 0.65)
2 (0.02, 0.51) (0.03, 0.20) (0.04, 0.71)
3 (0.01, 0.94) (0.05, 0.28) (0.08, 0.71)
4 (0.01, 4.64) (0.07, 0.40) (0.14, 0.74)
5 (0.04, 1.04) (0.12, 0.54) (0.18, 0.80)
6 (0.09, 0.94) (0.17, 0.70) (0.23, 0.88)
7 (0.19, 1.67) (0.25, 0.91) (0.28, 1.01)
8 (0.10, 3.85) (0.33, 1.16) (0.30, 1.07)
9 (0.27, 4.93) (0.45, 1.46) (0.31, 1.25)
10 (0.39, 3.94) (0.56, 1.79) (0.32, 1.44)
11 (0.45, 3.49) (0.70, 2.27) (0.31, 1.61)
12 (0.26, 6.06) (0.87, 2.99) (0.30, 1.87)
13 (0.28, 6.14) (1.09, 4.38) (0.30, 2.31)
14 (0.44, 4.26) (1.44, 9.56) (0.32, 4.07)
4.6.1 ECDF
While our proposed procedure was motivated by a desire to avoid making any assump-
tions about the existence or nature of the distribution of our quantity of interest {Θ}, we
note that a plot such as that given in Figure 1 may resemble an empirical CDF for the
“true” distribution F (Θ). As sample size increases, the confidence distribution estimates for
each θ(m) converge to the true values (θ(1), θ(2), ..., θ(K)). If it can further be assumed that
(θ(1), θ(2), ..., θ(K)) are a random sample from some overall distribution F (Θ), then it can be
seen that θ˜(q) = θ(￿qK￿+1) will converge, as K grows large, to F−1Θ (q).
4.7 Discussion
In this paper, we introduce a unified framework which simultaneously addresses two impor-
tant problems. By introducing a procedure for making inference on any ordered value of
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Figure 4.1: Confidence distribution estimates of treatment eﬀects from 14 studies of acetyl-
cysteine on nephropathy: Vertical and solid (dashed) lines represent 95% CI from fixed-eﬀects
(random-eﬀects) meta-analysis
a set of parameters, we may provide a summary of the treatment eﬀects observed over a
collection of studies without having to rely on any assumptions about the nature of or rela-
tionship between those treatment eﬀects, thus enabling a non-parametric, model-free form
of meta-analysis. While the resulting confidence interval from such a procedure will likely be
wider than those provided by methods with more restrictive assumptions, the general appli-
cability of our new method is appealing and may serve as a good point of comparison, just
as many analysts now present results corresponding to both fixed-eﬀects and random-eﬀects
meta-analysis models. Alternatively, our procedure also allows us to make inference on the
extreme values of a set of parameters, a well-established problem that has proven to be in-
tractable with respect to many statistical approaches. By taking advantage of the flexibility
aﬀorded by confidence distributions as functional estimators, as well as a tuning technique
that accounts for the unknown presence or absence of ties and near-ties in small-sample
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settings, we are now able to provide valid inference in a wide variety of settings.
4.8 Appendix
Proof of Theorem 4.1. (i) The first two results follow immediately from (4.13) and the
fact that |θˆi − θ(m)| ≤ |θˆi − θi| + |θi − θ(m)| = Op(N−1/2) for any θi ∈ ΘN . We only need to
prove (4.15).
Note that, θˆi ∼ (θi, s2i ), for any i, it follows that￿
i∈ΘN ciθˆi
￿￿
i∈ΘN ci −
￿
i∈ΘN ciθi
￿￿
i∈ΘN ci￿￿
i∈ΘN c
2
i s
2
i
￿{￿i∈ΘN ci}2 ∼ N(0, 1). (4.21)
Again, from (4.13) and the fact that |θi − θ(m)| = O(N−1/2) for any θi ∈ ΘN , we have￿K
i=1wi,(m)θˆi =
￿
i∈ΘN ciθˆi + op(1),
￿K
i=1w
2
i,(m)s
2
i =
￿
i∈ΘN c
2
i s
2
i + op(1),
￿K
i=1wi,(m) =￿
i∈ΘN ci + op(1) and
￿
i∈ΘN ciθi = {
￿
i∈ΘN ci} θ(m) +O(N−1/2). Thus, we have￿K
i=1wi,(m)θˆi
￿￿K
i=1wi,(m) − θ(m)￿￿K
i=1w
2
i,(m)s
2
i
￿{￿Ki=1wi,(m)}2 → N(0, 1), as N →∞ (4.22)
On the other hand, since ξ∗ =
￿K
i=1wi,(m)ξi/
￿K
i=1wi,(m) and ξi are CD random variables
from N(θˆi, s2i ), we have
ξ∗ −￿Ki=1wi,(m)θˆi￿￿Ki=1wi,(m)￿￿K
i=1w
2
i,(m)s
2
i
￿{￿Ki=1wi,(m)}2
￿￿￿￿Θˆ ∼ N(0, 1). (4.23)
It follows immediately the third result of (i).
(ii) Based on (4.22) and (4.23) and the definition of H∗(t), we have, for any 0 < s < 1
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and as N →∞,
P
￿
H∗(θ(m)) ≤ s
￿
= P
P
 ξ∗ −￿Ki=1wi,(m)θˆi￿￿Ki=1wi,(m)￿￿K
i=1w
2
i,(m)s
2
i
￿{￿Ki=1wi,(m)}2 ≤
θ(m) −￿Ki=1wi,(m)θˆi￿￿Ki=1wi,(m)￿￿K
i=1w
2
i,(m)s
2
i
￿{￿Ki=1wi,(m)}2
￿￿￿￿Θˆ
 ≤ s

= P
θ(m) −
￿K
i=1wi,(m)θˆi
￿￿K
i=1wi,(m)￿￿K
i=1w
2
i,(m)s
2
i
￿{￿Ki=1wi,(m)}2 ≤ Φ−1(s)
→ Φ(Φ−1(s)) = s. (4.24)
Thus, H∗(θ(m))→ Unif [0, 1], as N →∞. The conclusion of (ii) follows.
Proof of Lemma 4.1 Recall that the condition described in (4.13) is as follows:
lim
n→∞
wi,(m) =
￿
ci if ı ∈ Θ(m)T ,
0 if ı ￿∈ Θ(m)T ,
for i = 1, 2, . . . , K .
Without loss of generality, let θ1 < θ2 < . . . < θK . Also let θˆj ∼ N(θj, σ2j/nj) for each j
and define θˆ(j) : θˆ(1) ≤ θˆ(2) ≤ ... ≤ θˆ(K). Furthermore, suppose we are interested in θm.
Recall w[1]m,(m) = 1{θˆm = θˆ(m)} is a binary random variable that equals 1 with probability
P{θˆi = θˆ(m)}.
P{θˆm = θˆ(m)} <
￿
i<m
[P{θˆi < θˆm}]
￿
j>m
[P{θˆj > θˆm}]
=
￿ ￿
i<m
[P{θˆi < c}]P{θˆm = c}
￿
j>m
[P{θˆj > c}] dc
=
￿ ￿
i<m
[Φ(
c− θi
σi/
√
ni
)]φ(
c− θm
σm/
√
nm
)
￿
j>m
[Φ(
θj − c
σj/
√
nj
)] dc (4.25)
<
￿ θm+1−￿
θm−1+￿
￿
i<m
[Φ(
c− θi
σi/
√
ni
)]φ(
c− θm
σm/
√
nm
)
￿
j>m
[Φ(
θj − c
σj/
√
nj
)] dc
→
￿ θm+1−￿
θm−1+￿
φ(
c− θm
σm/
√
nm
) dc→ 1
Thus w[1]m,(m) converges in probability to 1.
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Because we have that w[1]m,(m) → 1 and
￿
iw
[1]
i,(m) = 1, then w
[1]
i,(m) → 0∀i ￿= m, thus
satisfying (4.13).
Noting that θˆj ∼ N(θj, σ2j/nj) and, unconditionally, ξj ∼ N(θj, 2σ2j/nj), we can replace
each σ2j with 2σ
2
j in the proof above, and the result remains unchanged.
Recall that w[3]i,(m) = 1{−bL ≤ (ξi − ξ(m)) ≤ bR}, where (bL, bR) ∝ τN , τN = O(N−δ), δ ∈
(0, 12). For i = m, we use the argument above that P{ξm = ξ(m)}→ 1, and so K
￿
ξi−ξ(m)
τN
￿
→
K
￿
0
τN
￿
= 1. For i ￿= m, (ξi − ξ(m)) converges in probability to Di = θi − θm. For i < m,
Di/τN → −∞, and thus K
￿
ξi−ξ(m)
τN
￿
→ 0. Similarly, for i > m, Di/τN → +∞, and thus
K
￿
ξi−ξ(m)
τN
￿
→ 0. Thus, we have satisfied (4.13).
Proof of Lemma 4.2. Recall that w[3]i,(m) = 1{−bL ≤ (ξi − ξ(m)) ≤ bR}, where
(bL, bR) ∝ τN , and τN = O(N−δ), with 0 < δ < 1/2. Let us denote cL = bL/τN , cR = bR/τN ,
so that cL, cR = O(1).
Now w[3]i,(m) = 1{−bL ≤ (ξi − ξ(m)) ≤ bR} = 1{−cL ≤ (ξi−ξ
(m))
τN
≤ cR}. Note that in
general, ξi = θˆi + ￿˜n, and θˆi = θi + ￿n, where both ￿˜n and ￿n = O(N−1/2). Substituting, we
have that (ξi − ξ(m)) = θi − θ(m) + ￿˜in − ￿˜(m)n + ￿in − ￿(m)n = θi − θ(m) +O(N−1/2).
Thus, when i ∈ Θ(m)T , θi = θ(m), then (ξi − ξ(m)) = O(N−1/2), (ξi−ξ
(m))
τN
= O(N−1/2+δ) =
o(1)⇒ (ξi−ξ(m))τN → 0 as N →∞, and so w
[3]
i,(m) → 1 as N →∞.
First, we address the conventional case where θi are constant in N.
When i ￿∈ Θ(m)T , θi ￿= θ(m), then (ξi − ξ(m)) = θi − θ(m) + O(N−1/2) = O(1), (ξi−ξ
(m))
τN
=
O(N δ)⇒ (ξi−ξ(m))τN →∞ as N →∞, and so w
[3]
i,(m) → 0 as N →∞.
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Now, if we instead have that dm = minj ￿∈Θ(m)T
|θj−θ(m)| is O(N−δ∗), for any δ∗ ∈ (0, 1/2),
our only requirement is that the convergence rate for τN , δ must be restricted to (δ∗, 1/2).
In this case, when i ￿∈ Θ(m)T , θi ￿= θ(m), then (ξi − ξ(m)) = O(N−δ∗), (ξi−ξ
(m))
τN
=
O(N δ−δ∗)⇒ (ξi−ξ(m))τN →∞ as N →∞, and so w
[3]
i,(m) → 0 as N →∞.
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